<!DOCTYPE html>
<html>

  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, user-scalable=no, initial-scale=0.95, maximum-scale=0.95, minimum-scale=0.95"/>
    <meta http-equiv="x-ua-compatible" content="IE=edge">
    <title>Liverpool HIV Interactions</title>
    <link rel="stylesheet" media="all" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv_site-0a478b945d0a5a038ce1c2c7353d4cdcc80f95b7d764296440f4a7790aac6305.css" />
    <!--[if IE 8]>
        <script src="//cdnjs.cloudflare.com/ajax/libs/es5-shim/4.0.5/es5-shim.min.js"></script>
        <style>
            .ng-hide {
                display: none !important;
            }
        </style>
    <![endif]-->
    <script src="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/application-558b3c2a3e06dc8db0be037ca1d2b0a8b417b18dfe38e0d45ee242ed38ca7613.js"></script>
    
    <meta name="csrf-param" content="authenticity_token" />
<meta name="csrf-token" content="6lMBPv75G14NmiN9yDJuC9GHoI6IpW19sVKyBaN+oR14HVThrqTWCrl5C8vwcuTwZo1ocIPyJzXInSy0Nl8Riw==" />
    
    <link rel="icon" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-6af0467185368caf8c843f5fbf2095eb85d3057e8a2dbfadc5ffbb7bda4d8f59.ico" sizes="32x32">
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-152px-8970667e12c076f671daad84dcacda13b40c6f22672b38c55ad61f72e857b460.png">
    <link rel="apple-touch-icon-precomposed" sizes="144x144" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-144px-24f03e597ce22e8446280458d4f244e00620008785ccc07c52ae61f18f50911a.png">
    <link rel="apple-touch-icon-precomposed" sizes="120x120" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-120px-e5b3af06dec7a9a0f9965209b7ffba504447096d086d79b26dbb8f1962b6251f.png">
    <link rel="apple-touch-icon-precomposed" sizes="114x114" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-114px-106d37d88ee6e9a4275d2de639a68b139ae7d66416b4bb64b317a37e8b2673e6.png">
    <link rel="apple-touch-icon-precomposed" sizes="72x72" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-72px-b24efd122931fef6f36ce176141fd6d47a46fa7e0770b5f98e8e2eec849d57ac.png">
    <link rel="apple-touch-icon-precomposed" sizes="57x57" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-57px-154d723ded7ac95257566911bfbe8b158829cf0ada223a9f737d453dbd3e293b.png">
    <link href='http://fonts.googleapis.com/css?family=Varela+Round' rel='stylesheet' type='text/css'>
    <!-- start Mixpanel --><script type="text/javascript">(function(e,b){if(!b.__SV){var a,f,i,g;window.mixpanel=b;b._i=[];b.init=function(a,e,d){function f(b,h){var a=h.split(".");2==a.length&&(b=b[a[0]],h=a[1]);b[h]=function(){b.push([h].concat(Array.prototype.slice.call(arguments,0)))}}var c=b;"undefined"!==typeof d?c=b[d]=[]:d="mixpanel";c.people=c.people||[];c.toString=function(b){var a="mixpanel";"mixpanel"!==d&&(a+="."+d);b||(a+=" (stub)");return a};c.people.toString=function(){return c.toString(1)+".people (stub)"};i="disable time_event track track_pageview track_links track_forms register register_once alias unregister identify name_tag set_config people.set people.set_once people.increment people.append people.union people.track_charge people.clear_charges people.delete_user".split(" ");
for(g=0;g<i.length;g++)f(c,i[g]);b._i.push([a,e,d])};b.__SV=1.2;a=e.createElement("script");a.type="text/javascript";a.async=!0;a.src="undefined"!==typeof MIXPANEL_CUSTOM_LIB_URL?MIXPANEL_CUSTOM_LIB_URL:"file:"===e.location.protocol&&"//cdn.mxpnl.com/libs/mixpanel-2-latest.min.js".match(/^\/\//)?"https://cdn.mxpnl.com/libs/mixpanel-2-latest.min.js":"//cdn.mxpnl.com/libs/mixpanel-2-latest.min.js";f=e.getElementsByTagName("script")[0];f.parentNode.insertBefore(a,f)}})(document,window.mixpanel||[]);
mixpanel.init("cac4e9c0b9aef2c3bc30326ca7d1683f");</script><!-- end Mixpanel -->
    <!--[if lt IE 8]>
  <p class="browserupgrade">You are using an <strong>outdated</strong> browser. Please <a href="http://browsehappy.com/">upgrade your browser</a> to improve your experience.</p>
<![endif]-->

<!--[if lte IE 9]>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv.min.js"></script>
<![endif]-->

    <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-75467942-1', 'auto');
  ga('send', 'pageview');
</script>

  </head>

  <body>
    <div class="header">
  <div class="inner-wrapper">
    <a class="logo" href="/">
      <p class="logo-icon"></p><p>HIV Drug Interactions</p>
</a>    <div class="header-right-column">
      <a href="https://www.liverpool.ac.uk/" target="_blank" class="uol-header-logo"></a>
          <div class="header-button-stack">
            <a href="https://alumni.liv.ac.uk/give-back/donate/drug-interactions-donation-page" target="_blank" class="header-right-column-button">
              <p>Donate Now</p>
              <p class="header-button-icon"></p>
            </a>

            <div class="apps-dropdown-nav-wrapper">
              <a href="#" class="header-right-column-button apps-dropdown-button">
                <p>Apps</p>
                <p class="header-button-icon"></p>
              </a>
                <div class="apps-dropdown-nav">
                  <a href="https://itunes.apple.com/gb/app/liverpool-hiv-ichart/id979962744?mt=8" target="_blank" class="appstore-link">
                    <p class="icon"></p>
                    <p>Download from the AppStore</p>
                  </a>
                  <a href="https://play.google.com/store/apps/details?id=com.liverpooluni.icharthiv&hl=en_GB" target="_blank" class="google-play-link">
                    <p class="icon"></p>
                    <p>Download from Google Play</p>
                  </a>
                </div>
            </div>
          </div>


    </div>


    <a href="javascript:;" class="mobile-nav-icon">
      <p></p>
      <p></p>
      <p></p>
    </a>
    <a href="https://www.liverpool.ac.uk/" target="_blank" class="uol-header-logo mobile-uol"></a>

  </div>
</div>
<a class="mobile-interaction-link" href="/checker">
  <p>Interaction Checker</p>
  <p class="header-button-icon"></p>
</a><a href="https://alumni.liv.ac.uk/give-back/donate/drug-interactions-donation-page" target="_blank" class="mobile-interaction-link donate-mobile-link">
  <p>Donate Now</p>
  <p class="header-button-icon"></p>
</a>

<div class="navigation">
  <div class="inner-wrapper">


    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Interaction Charts</a>

      <div class="drop-down-nav interaction-charts">
        <a href="/checker">Interaction Checker</a>
        <a href="/drug_queries/new">Interaction Checker Lite</a>
        <a href="/view_all_interactions/new">View All Checker</a>
        <a href="/printable_charts">Printable Charts</a>
        <a href="/treatment_selectors">Treatment Selectors</a>
      </div>
    </div>

    <a href="/site_updates">Site Updates</a>
    <!--
    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Site News/Updates</a>
      <div class="drop-down-nav site-news">
        <a href="/articles">Latest Articles</a>
        <a href="/site_updates">Site Updates</a>
      </div>
    </div>
    -->




    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">About Us</a>
      <div class="drop-down-nav about-drop-down">
        <a href="/mission">Mission Statement</a>
        <a href="/board">Editorial Board</a>
      </div>
    </div>

    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Pharmacology Resources</a>
      <div class="drop-down-nav resources-drop-down">
        <a href="/fact_sheets">Fact Sheets</a>
      </div>
    </div>

    <a href="/feedback">Contact Us</a>

    <a href="/support-us">Support Us</a>

  </div>
</div>

    <div class="row">
  <div class="col-lg-12">


  </div>
</div>

    <div class="inner-body-wrapper">
  <div class="inner-wrapper">

    <div class="interaction-block-single-page-wrapper">


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Acarbose</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and by the microbial flora.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Acenocoumarol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as acenocoumarol is mainly metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Acetazolamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction. Acetazolamide is primarily excreted unchanged via the kidneys, there is therefore little potential for interaction with abacavir via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Acetazolamide is fairly rapidly absorbed from the gastro-intestinal tract with peak plasma concentrations occurring about 2 hours after administration by mouth. It has been estimated to have a plasma half-life of about 4 hours. It is tightly bound to carbonic anhydrase and accumulates in tissues containing this enzyme, particularly red blood cells and the renal cortex. It is also bound to plasma proteins. It is excreted unchanged in the urine; renal clearance being enhanced in alkaline urine.<br /><em>Diamox&#174; (Acetazolamide) Tablets 250mg UK Summary of Product Characteristics, Mercury Pharma Group, updated November 2011</em></p>
<p>Acetazolamide is excreted unchanged by the kidneys via tubular secretion and passive reabsorption. After administration of the oral tablets or after IV injection, 70&#8211;100% (average 90%) of the dose is excreted in urine within 24 hours; 47% of the dose is excreted within 24 hours following administration of the extended-release capsules.<br /><em>AHFS Drug Information, published by the American Society of Health-System Pharmacists Inc, January 2009</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Aciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as aciclovir is eliminated renally via glomerular filtration and active renal secretion by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Acitretin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as acitretin undergoes isomerisation and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Adefovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as adefovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Adrenaline (Epinephrine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Adrenaline is rapidly inactivated, mostly in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). There is therefore little potential for interaction with abacavir via modulation of, or competition for metabolic or elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Adrenaline is a naturally occurring catecholamine secreted by the adrenal medulla in response to exertion or stress. Adrenaline is rapidly inactivated in the body, mostly in the liver by the enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Much of a dose of adrenaline is excreted as metabolites in urine. The plasma half-life is about 2-3 minutes. However, when given by subcutaneous or intramuscular injection, local vasoconstriction may delay absorption so that the effects may last longer than the half-life suggests.<br /><em>Adrenaline (Epinephrine) Injection BP 1 in 1000 UK Summary of Product Characteristics, Hameln pharmaceuticals ltd, updated August 2010</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>African Potato</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on the metabolic data there is little potential for pharmacokinetic interactions.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Agomelatine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as agomelatine is metabolised predominantly by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Albendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Albendazole is thought to be predominantly metabolised by CYP450 enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Albendazole rapidly undergoes extensive first-pass metabolism in the liver, and is generally not detected in plasma. Albendazole sulphoxide is the primary metabolite, which is thought to be the active moiety in effectiveness against systemic tissue infections. Albendazole sulphoxide and its metabolites appear to be principally eliminated in bile, with only a small proportion appearing in the urine.<br /><em>Zentel&#174; Australian Product Information, GlaxoSmithKline Updated January 2009<br />Eskazole&#174; Australian Product Information, GlaxoSmithKline Updated September 2010</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Alcohol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Abacavir has no effect on the pharmacokinetics of alcohol. Alcohol decreases the elimination of abacavir causing an increase in overall exposure. These findings are not considered clinically significant. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The metabolism of abacavir is altered by concomitant ethanol resulting in an increase in AUC of abacavir of about 41%. These findings are not considered clinically significant. Abacavir has no effect on the metabolism of ethanol.<br /><em>Ziagen Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2011.</em></p>
<p>Due to their common metabolic pathways via alcohol dehydrogenase, the pharmacokinetic interaction between abacavir and ethanol was studied in 24 HIV-infected male patients. Each patient received the following treatments on separate occasions: a single 600-mg dose of abacavir, 0.7 g/kg ethanol (equivalent to 5 alcoholic drinks), and abacavir 600 mg plus 0.7 g/kg ethanol. Coadministration of ethanol and abacavir resulted in a 41% increase in abacavir AUC and a 26% increase in abacavir half life. In males, abacavir had no effect on the pharmacokinetic properties of ethanol, so no clinically significant interaction is expected in men. This interaction has not been studied in females. <br /><em>Ziagen Prescribing Information, ViiV Healthcare, May 2012.</em></p>
<p>The interaction between abacavir (600 mg single dose) and ethanol (0.7g/kg single dose) was evaluated in 24 HIV-infected males. Ethanol pharmacokinetic parameters were unchanged with abacavir coadministration. There was no evidence that coadministration of abacavir interfered with ethanol metabolism and there were no disulfiram-type reactions in any subject receiving abacavir and ethanol. Abacavir AUC increased by 41% and Cmax increased by 15% and half life by 26%. While these changes were statistically significant, they were not considered clinically significant. The increased plasma abacavir concentrations observed in this study were well within the range seen in previous studies where no additional safety concerns were demonstrated. <br /><em>Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. McDowell JA, et al. Antimicrobial Agents Chemother, 2000, 44:1686-1690.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Alcuronium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Alcuronium is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>An intravenous (IV) single-bolus injection of alcuronium (0.25 mg/kg = ED95) was administered to 10 patients undergoing maxillofacial surgery during nitrous-oxide opioid anesthesia. Alcuronium neuromuscular block, plasma concentration, and renal elimination (HPLC assay) were measured during the 12-h after its administration. Two hours after the injection of alcuronium, partial recovery from the neuromuscular block had occurred from 100% to 26% +/- 24% depression of twitch tension, although less than 25% of the injected dose was recovered from the urine. The 12-h plasma concentration and urinary recovery were 0.1 +/- 0.08 mg/L and 61% +/- 20%, respectively. Recovery from neuromuscular block was dominated by intercompartmental distribution rather than by renal elimination. Alcuronium does not undergo biodegradation; apart from negligible biliary excretion, the kidney represented the only excretory pathway.<br /><em>Diefenbach C, K&#252;nzer T, Buzello W, Theisohn M. Alcuronium: a pharmacodynamic and pharmacokinetic update. Anesth Analg. 1995 Feb;80(2):373-7</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Alendronic Acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary) </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Alfentanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alfentanil undergoes extensive CYP3A4 metabolism. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Alfuzosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alfuzosin is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Aliskiren</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized and is mainly excreted unchanged in faeces. P-glycoprotein is a major determinant of aliskiren bioavailability.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Allopurinol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Almotriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Almotriptan is partly eliminated unchanged in the urine and partly metabolized (mainly via monoamine oxidase-A and to a lesser extent by CYP3A4, CYP2D6 and flavin monooxygenase).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Aloe vera</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Aloe vera is only a weak inhibitor of CYPs in vitro and therefore is unlikely to cause clinically significant interactions. It does not inhibit P-gp and there is no evidence to suggest it impacts UGTs.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Alosetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. In vitro data indicate that alosetron is metabolized by CYPs 2C9, 3A4 and 1A2, with in vivo data suggesting that CYP1A2 plays a more prominent role.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Alprazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on  metabolism and clearance a clinically significant interaction is unlikely as alprazolam is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Aluminium hydroxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Aluminium hydroxide is slowly but perhaps incompletely converted to aluminium chloride in the stomach. Some absorption of soluble aluminium salts occurs from the gastro-intestinal tract with some excretion in the urine. Some unabsorbed aluminium hydroxide combines with phosphates and some form carbonates and salts of fatty acids, all these salts are excreted in the faeces.<br /><em>Alu-Cap&#174; (Aluminium hydroxide) Capsules UK Summary of Product Characteristics, Meda Pharmaceuticals, updated June 2012</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amantadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amantadine is mainly eliminated renally by glomerular filtration and active secretion. A bicarbonate dependent organic cation transporter has been identified as the major uptake transporter of amantadine in the renal proximal tubule.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amikacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amikacin is eliminated renally by glomerular filtration. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amiloride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amiloride is eliminated unchanged by the kidney.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amiodarone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amiodarone is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amisulpride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amitriptyline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amitriptyline is metabolized predominantly by CYP2D6 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amlodipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amlodipine is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amodiaquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amodiaquine is mainly metabolized by CYP2C8 to N-desethylamodiaquine, an active metabolite but less potent than the parent compound.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amoxicillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly eliminated unchanged in the kidney and in vitro data indicate that it is a substrate of OAT3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amphetamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amphetamine is metabolized by CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amphotericin B</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amphotericin is not appreciably metabolized and is eliminated to a large extent in the bile. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ampicillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ampicillin is predominantly eliminated unchanged via renal pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ampicillin is excreted mainly in the bile and urine with a plasma half life of 1-2 hours.<br /><em>Penbritin&#174; (ampicillin) UK Summary of Product Characteristics, Chemidex Pharma Ltd. Updated February 2009</em></p>
<p>Ampicillin is metabolised to some extent to penicilloic acid which is excreted in the urine. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion; it is reduced by probenecid. About 20 to 40% of an oral dose may be excreted unchanged in the urine in 6 hours; urinary concentrations have ranged from 0.25 to 1 mg/mL after a dose of 500 mg. After parenteral use about 60 to 80% is excreted in the urine within 6 hours.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 20-August-2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Amyl nitrate (Poppers)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Amyl nitrate is metabolized rapidly by hydrolytic denitration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Anastrozole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated by UGT1A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Anidulafungin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperature.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Antacids</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as antacids are unlikely to alter abacavir absorption.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Apixaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is metabolized by CYP3A4 and to a lesser extent by CYP1A2, CYP2C8, CYP2C9 and CYP2C19.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Apomorphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Aprepitant</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Aripiprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as aripiprazole is metabolized by CYP3A4 and CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Artemisinin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Artemisinins undergo rapid metabolism via several CYP450 (CYPs 3A4, 2A6, 2B6) and the active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolized via UGTs 1A9 and 2B7. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ascorbic Acid (Vitamin C)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ascorbic acid is oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate - 2 - sulphate. Large doses are rapidly excreted in the urine when in excess of the requirements of the body. There is therefore little potential for interaction with abacavir via modulation of, or competition for metabolic pathways. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Ascorbic acid is readily oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate - 2 - sulphate. Metabolic turnover appears to be greater in females than males. Large doses are rapidly excreted in the urine when in excess of the requirements of the body and after an intravenous dose, about 40% is excreted in 8 hours, which is increased to about 70% after tissue saturation. The amount of unchanged drug is dose dependent; in women the excretion of ascorbic acid appears to vary with the stage of the menstrual cycle and it is decreased when taking oral contraceptives. Oxalic acid and ascorbate - 2 - sulphate are excreted in the urine.<br /><em>Ascorbic Acid Injection 500mg/5ml UK Summary of Product Characteristics, UCB Pharma Limited, updated March 2009</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Asenapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (mainly CYP1A2, with minor contributions from CYP3A4 and CYP2D6).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Asparaginase</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolic profiles of both drugs, there is little potential for pharmacokinetic interaction.  Limited data suggest that asparaginase is likely to be eliminated by the reticuloendothelial system.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Limited data suggest that asparaginase is likely to be eliminated by the reticuloendothelial system. Less than 0.1% of a total injected dose is recovered in urine.&nbsp; Uptake by receptor-mediated endocytosis has also been suggested as a mechanism of asparaginase elimination<br /><em>Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Narta UK, Kanwar SS, Azmi W. Crit Rev Oncol Hematol. 2007 Mar;61(3):208-21.<br />Comparative pharmacokinetic studies of three asparaginase preparations. Asselin BL, Whitin JC, Coppola DJ et al. J Clin Oncol. 1993 Sep;11(9):1780-6.<br />Elimination of l-asparaginase in children treated for acute lymphoblastic leukemia. Brueck M, Koerholz D, Nuernberger W et al. Dev Pharmacol Ther. 1989;12(4):200-4.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Aspirin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to salicylic acid and then further metabolized mainly by glucuronidation (by several UGT, major UGT1A6). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Astemizole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as astemizole is metabolized by CYPs 2D6, 2J2 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Atazanavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of abacavir (600 mg once daily) and atazanavir/ritonavir (300/100 mg once daily) had no effect on atazanavir or ritonavir pharmacokinetics, but decreased abacavir AUC (17%) and Cmax (20%). These changes are unlikely to be clinically significant. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The co-administration of atazanavir/ritonavir with abacavir is not expected to significantly alter the exposure of abacavir. <br /><em>Reyataz Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, <em>April 2014</em>.</em></p>
<p>Coadministration of abacavir (600 mg once daily) and atazanavir/ritonavir (300/100 mg once daily) was studied in 12 HIV+ subjects. There was no effect on atazanavir or ritonavir pharmacokinetics, but abacavir AUC decreased by 17% and Cmax decreased by 20%. <br /><em>Abacavir plasma pharmacokinetics in the absence and the presence of atazanavir/ritonavir or lopinavir/ritonavir) and vice versa in HIV+ patients. Waters L, et al. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007, abstract 557.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Atenolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atenolol is mainly eliminated unchanged by the kidney, predominantly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Atorvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atorvastatin is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Atovaquone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atovaquone is mainly eliminated unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Atropine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction when atropine is used either systemically or as eye drops. Although metabolism of atropine is not fully elucidated, up to 50% is excreted unchanged via the kidneys. There is therefore little potential for clinically significant interactions with abacavir via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Systemic use: Atropine is metabolised in the liver by oxidation and conjugation to give inactive metabolites. About 50% of the dose is excreted within 4 hours and 90% in 24 hours in the urine, about 30 to 50% as unchanged drug.<br /><em>Atropine Injection BP Minijet UK Summary of Product Characteristics, International Medication Systems (UK) Ltd, updated October 2005</em></p>
<p>Ocular use: Atropine is also absorbed by mucous membranes but less readily from the eye and skin, although significant toxicity can sometimes occur through absorption of excessive eye drops. Atropine is metabolised by hepatic oxidation and conjugation to inactive metabolites, with about 2% undergoing hydrolysis to tropine and tropic acid. About 30% of the dose is excreted unchanged in the urine. Only trace amounts of the dose are eliminated in the faeces.<br /><em>Minims Atropine Sulphate 1%, Eye drops solution UK Summary of Product Characteristics, Bausch &amp; Lomb U.K Limited, updated July 2012</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Azathioprine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is metabolized to 6-mercaptopurine which is further inactivated by xanthine oxidase and thiopurine methyltransferase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Azithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as azithromycin is mainly eliminated via biliary excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Baclofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as baclofen is primarily eliminated by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Beclometasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450 but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bedaquiline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bedaquiline is metabolised by CYP3A4 and mainly eliminated in faeces. There are no clinical data on the safety and efficacy of bedaquiline when coadministered with antiretroviral agents.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bendroflumethiazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on  metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is eliminated by hepatic metabolism (70%) and excreted unchanged in the urine (30%) via OAT1 and OAT3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Benserazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as benserazide is hydrolysed to trihydroxybenzylhydrazine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Benznidazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning the metabolism/elimination of benznidazole, there is little potential for significant interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Benznidazole is absorbed from the gastrointestinal tract after oral doses (&gt; 90% bioavailability) and is widely distributed throughout the body. More than 40% of the drug is bound to plasma protein. The peak plasma concentration occurs after 3 to 4 hours and the half-life is about 12 hours. It is metabolised in the liver and more than 70% of the metabolites are excreted by the kidneys; about 30% of a dose is excreted in the faeces.<br /><em>Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 1979; 29: 1611&#8211;14.</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bepridil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bepridil is mainly metabolized by CYP2D6 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Betamethasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Betamethasone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bexarotene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Bexarotene is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bezafibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as half of bezafibrate dose is eliminated unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Biperiden</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as biperiden undergoes hydroxylation in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bisacodyl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bisoprolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bleomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bleomycin is inactivated by a cytosolic enzyme, bleomycin hydrolase, and two thirds of the administered drug is excreted unchanged in urine, probably by glomerular filtration. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Boceprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as boceprevir is metabolized by aldoketoreductase and CYP3A.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bortezomib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bortezomib is mainly metabolized by CYP3A4 and 2C19 and to a lesser extent by CYPs 1A2, 2D6 and 2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bosentan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bosentan is metabolized by CYP3A4 and CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bromazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bromazepam undergoes oxidative biotransformation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Budesonide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as budesonide is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bupivacaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Bupivacaine is predominantly metabolized via CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Bupivacaine is extensively metabolised in the liver, predominately by aromatic hydroxylation to 4-hydroxy-bupivacaine and N-dealkylation to PPX, both mediated by cytochrome P4503A4. About 1% of bupivacaine is excreted in the urine as unchanged drug in 24 h and approximately 5% as PPX. The plasma concentrations of PPX and 4-hydroxy-bupivacaine during and after continuous administration of bupivacaine are low as compared to the parent drug. <br /><em>Marcain&#174; Polyamp Steripack 0.25% and 0.5% UK Summary of Product Characteristics, AstraZeneca UK Limited, updated May 2012</em></p>
<p>Bupivacaine is extensively metabolized in the liver predominantly by aromatic hydroxylation to 4-hydroxy-bupivacaine and N-dealkylation to 2,6-pipecoloxylidine (PPX), both mediated by cytochrome P450 3A4. The terminal half-life of bupivacaine in adults is 2.7 hours, and in neonates it is prolonged up to eight hours. The kidney is the main excretory organ for most local anaesthetics and their metabolites. About 1% of bupivacaine is excreted in the urine as unchanged drug in 24 h and approximately 5% as PPX. The plasma concentrations of PPX and 4-hydroxy-bupivacaine during and after continuous administration of bupivacaine are low as compared to the parent drug.<br /><em>Sensorcaine&#174; Bupivacaine Hydrochloride Injection USP Canadian Product Monograph, AstraZeneca Canada Inc, Last revised: February 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Buprenorphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as buprenorphine and its active metabolite (norbuprenorphine) are glucuronidated by several UGTs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Bupropion</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bupropion is primarily metabolized by CYP2B6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Buspirone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as buspirone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Caffeine citrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as caffeine is mainly metabolized by CYP1A2. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Calcium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium is eliminated through faeces, urine and sweat.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Candesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as candesartan is mainly eliminated unchanged via urine and bile.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cannabis</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. THC, the principal psychoactive constituent of cannabis, is metabolized mainly by CYP2C9 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Capecitabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capecitabine is activated by sequential enzyme reactions to fluorouracil.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Capreomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Capreomycin is predominantly excreted via the kidneys as unchanged drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Capreomycin is excreted in the urine, essentially unaltered, and approximately 50% of a 1g intramuscular dose is excreted within 12 hours.<br /><em>Capreomycin Injection Summary of Product Characteristics King Pharmaceuticals Ltd, updated April 2010<br />Capastat&#174; (capreomycin) US Prescribing Information, Eli Lilly &amp;Co. updated January 2008</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Captopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, based on metabolism and clearance a clinically significant interaction is unlikely as captopril is largely excreted in the urine (40-50% as unchanged drug, the rest as disulfide and other metabolites).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Carbamazepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase carbamazepine concentrations due to competition for glucuronidation (carbamazepine is glucuronidated by UGT2B7). The clinical relevance of this interaction is unknown as the importance of glucuronidation in the overall metabolic process of carbamazepine is controversial. Perform TDM for carbamazepine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Carbidopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbidopa is partly metabolized and partly eliminated unchanged (30% of the total urinary excretion). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Carbimazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Carbimazole is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (also known as methimazole).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Carboplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Carboplatin is excreted primarily by renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Carboplatin is excreted primarily by glomerular filtration in urine, with recovery of 65% of a dose within 24 hours. Most of the drug is excreted within the first 6 hours. Approximately 32% of a given dose of carboplatin is excreted unchanged.<br /><em>Carboplatin 10 mg/ml Intravenous Infusion, UK Summary of Product Characteristics, Hospira UK Ltd, updated June 2009<br />Carboplatin Injection, US Prescribing Information, Hospira Inc, updated August 2007</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Carvedilol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, with additional metabolism via CYP2D6 and to a lesser extent 2C9 and 1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Caspofungin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cat&#39;s Claw (Uncaria tomentosa)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cats claw was demonstrated to strongly inhibit CYP3A4 in vitro, but abacavir&nbsp;does not undergo CYP3A4 metabolism.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cefalexin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged renally by glomerular filtration and tubular secretion via OAT1 and MATE1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cefazolin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cefazolin is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours. <br /><em>Cefazolin for Injection, US Prescribing Information, Pfizer Labs, Issued April 2009</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cefixime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cefixime is predominantly eliminated unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Cefixime is predominantly eliminated as unchanged drug in the urine. Glomerular filtration is considered the predominant mechanism. Metabolites of cefixime have not been isolated from human serum or urine.<br /><em>Suprax&#174; tablets (Cefixime) Summary of Product Characteristics, Sanofi-Aventis, updated November 2010</em></p>
<p>Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours. In animal studies, it was noted that cefixime is also excreted in the bile in excess of 10% of the administered dose. There is no evidence of metabolism of cefixime in vivo. <br /><em>Suprax&#174; (cefixime) US Prescribing Information, Lupin Pharmaceuticals INC, updated November 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cefotaxime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cefotaxime is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M2 and M3) account for about 20-25%. They lack bactericidal activity.<br /><em>Cefotaxime for injection US Prescribing Information, Pfizer Labs, updated December 2009</em></p>
<p>Cefotaxime is partially metabolised prior to excretion. The principal metabolite is the microbiologically active product, desacetyl-cefotaxime. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime. Plasma clearance is reported to be between 260 and 390ml/minute and renal clearance 145 to 217 ml/minute.<br />Probenecid interferes with renal tubular transfer of cefotaxime delaying its excretion and increasing the plasma concentration.<br /><em>Cefotaxime for injection Summary of Product Characteristics, Wockhardt UK Ltd, updated August 2008</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ceftazidime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ceftazidime is predominantly eliminated unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ceftazidime is not metabolised in the body and is excreted unchanged in the active form into the urine by glomerular filtration. Approximately 80 to 90% of the dose is recovered in the urine within 24 hours. Less than 1% is excreted via the bile, significantly limiting the amount entering the bowel.<br /><em>Fortum&#174; 500 injection (ceftazidime) Summary of Product Characteristics, GlaxoSmithKline UK, updated August 2009</em></p>
<p>Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period. After the IV administration of single 500-mg or 1-g doses, approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose appeared in the urine between 4 and 8 hours later. The calculated plasma clearance of approximately 115 mL/min indicated nearly complete elimination of ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the elimination kinetics of ceftazidime, suggesting that ceftazidime is eliminated by glomerular filtration and is not actively secreted by renal tubular mechanisms.<br /><em>Fortaz&#174; (ceftazidime for injection) US Prescribing Information, GlaxoSmithKline, updated August 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ceftriaxone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ceftriaxone is eliminated mainly as unchanged drug; approximately 60% of the dose being excreted in the urine, almost exclusively by glomerular filtration, and the remainder via the biliary and intestinal tracts. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ceftriaxone is eliminated mainly as unchanged drug; approximately 60% of the dose being excreted in the urine (almost exclusively by glomerular filtration) and the remainder via the biliary and intestinal tracts. The elimination of ceftriaxone is not altered by probenecid<br /><em>Rocephin&#174; (ceftriaxone) 250mg, 1g and 2g vials Summary of Product Characteristics, Roche Products Limited, updated May 2011</em></p>
<p>Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds. The elimination of ceftriaxone is not altered by co-administration with probenecid.<br /><em>Rocephin&#174; (ceftriaxone sodium) for injection, US Prescribing Information, Genentech USA, Inc, updated November 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Celecoxib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as celecoxib is metabolised mainly by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cetirizine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Chlorambucil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorambucil is almost completely metabolized (little is known about chlorambucil metabolism in humans, most probably non CYP mediated) and has extremely low urinary excretion. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Chloramphenicol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Chloramphenicol is predominantly metabolized by glucuronidation mediated by UGT2B7, and abacavir is metabolised by both alcohol dehydrogenase and glucuronidation. There is little potential for a clinically significant interaction via competition for metabolic pathways.  </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The primary UGT enzymes responsible for chloramphenicol O-glucuronidation were evaluated in vitro. Reaction phenotyping for the glucuronidation of chloramphenicol with 12 expressed human liver UGT isoforms has identified UGT2B7 as having the highest activity for 3-O- and 1-O-chloramphenicol glucuronidation with minor contributions from UGT1A6 and UGT1A9. The formation of 1-O-chloramphenicol glucuronide by pooled HLM and expressed UGT2B7 exhibited substrate inhibition kinetics with apparent K(m) values of 408.2 and 115.0 microM, respectively. Azidothymidine (AZT) and hyodeoxycholic acid (substrates of UGT2B7) inhibited 3-O- and 1-O-chloramphenicol glucuronidation in pooled HLMs. In 10 donor HLM preparations, both chloramphenicol 3-O- and chloramphenicol 1-O-glucuronidation showed a significant correlation with AZT glucuronidation (UGT2B7) at 30 microM chloramphenicol. These results suggest that UGT2B7 is the primary human hepatic UDP-glucuronosyltransferase isoform catalyzing 3-O- and 1-O-chloramphenicol glucuronidation with minor contributions from UGT1A6 and UGT1A9.<br /><em>Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol. Chen M, LeDuc B, Kerr S, Howe D, Williams DA. Drug Metab Dispos. 2010 Mar;38(3):368-75.</em> </p>
<p>Abacavir is primarily metabolised by the liver with approximately 2% of the administered dose being renally excreted, as unchanged compound. The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5'-carboxylic acid and 5'-glucuronide which account for about 66% of the administered dose. The metabolites are excreted in the urine<br /><em>Ziagen&#174; 300 mg Film Coated Tablets, Summary of Product Characteristics, updated November 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Chlordiazepoxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolized by hepatic microsomal enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Chloroquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Chloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). Due to the multiple elimination pathways, a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Chlorphenamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Chlorphenamine is predominantly metabolized in the liver via CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Chlorphenamine is metabolised to the monodesmethyl and didesmethyl derivatives. About 22% of an oral dose is excreted unchanged in the urine.<br /><em>Piriton&#174; (Chlorphenamine) Tablets&nbsp; UK Summary of Product Characteristics, GlaxoSmithKline Consumer Healthcare, updated May 2010</em></p>
<p>Eight healthy volunteers received a single 8mg oral dose of rac-chlorphenamine either given alone or following administration of quinidine 50mg every 6 h for 2 days prior to the study day and every 6 h thereafter until the end of the study. For (S)-(+)-chlorphenamine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94 (P&lt;0.01), a reduction in CLoral to 0.22 l h-1 kg-1 (P&lt;0.01), and a prolongation of elimination half-life from 18.0 h to 29.3 h (P&lt;0.001). Administration of quinidine decreased CLoral for (R)-(-)-chlorphenamine to 0.60+/-0.10 l h-1 kg-1 (P&lt;0.005). In CYP2D6 poor metabolizers, systemic exposure was greater after chlorphenamine alone than in extensive metabolizers, and administration of quinidine resulted in a slight increase in CLoral. Stereoselective elimination of chlorphenamine occurs in humans, with the most pharmacologically active (S)-(+)-enantiomer cleared more slowly than the (R)-(-)-enantiomer. CYP2D6 plays a role in the metabolism of chlorphenamine in humans.<br /><em>The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorphenamine. Yasuda SU, Zannikos P, Young AE et al. Br J Clin Pharmacol. 2002 May;53(5):519-25.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Chlorpromazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorpromazine is metabolized mainly by CYP2D6, but also CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Chlortalidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as chlortalidone is mainly excreted unchanged in the urine and faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ciclosporin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ciclosporin is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cidofovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cidofovir is mainly eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cilazapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cilazapril is mainly eliminated unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cimetidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cimetidine is eliminated primarily by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ciprofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged by the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolized and partially cleared through the bile and intestine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cisapride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cisapride is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cisatracurium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisatracurium undergoes mainly (80% of overall elimination) spontaneous degradation in plasma and tissues at physiological pH and temperature (Hofmann elimination).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cisplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cisplatin is eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Citalopram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolized by CYP2C19 (38%), 2D6 (31%) and 3A4 (31%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clarithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as clarithromycin is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clavulanic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Clavulanic acid is extensively metabolized (likely by a non CYP mediated pathway) and excreted in the urine by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clindamycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Clindamycin is metabolized by CYP3A4 with some metabolites having antibacterial activity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clobetasol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely with the topical use of clobetasol.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clofazimine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Three clofazimine  metabolites, two glucuronides, have been identified in urine, however clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. As glucuronidation has a minor role in clofazimine elimination, interaction with abacavir via this mechanism is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)<br /><em></em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clofibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolyzed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clomifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. CYP2D6 is thought to have a role in clomifene metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Based on early studies with 14C-labeled clomiphene citrate, the drug was shown to be readily absorbed orally in humans and excreted principally in the feces. Cumulative urinary and fecal excretion of the 14C averaged about 50% of the oral dose and 37% of an intravenous dose after 5 days. Mean urinary excretion was approximately 8% with fecal excretion of about 42%.<br /><em>Clomid&#174; (clomiphene citrate tablets USP) US Prescribing Information, Sanofi-aventis U.S. revised June 2006</em></p>
<p>A study aimed to define the role of CYP2D6 and CYP3A4 in the in vitro metabolism of enclomiphene, the more active isomer of clomiphene. Enclomiphene (25 microM) was incubated with human liver microsomes (from 4 extensive (EM) and 1 poor metaboliser with respect to CYP2D6) and with microsomes from lymphoblastoid cells expressing CYP2D6. Microsomes from all the EM livers and recombinant CYP2D6 metabolised enclomiphene (the disappearance of drug ranged from 40-60%). No metabolism was detected in microsomes from the PM liver. Quinidine (1 microM) completely inhibited the metabolism of enclomiphene by all the EM livers and by recombinant CYP2D6 (p&lt;0.001, one way ANOVA). Ketoconazole (2 microM) had no significant effect on enclomiphene metabolism in 3 out of the 4 EM livers. The extent of enclomiphene metabolism was correlated with the amount of CYP2D6 present (p&lt;0.001, Pearson correlation test). The findings indicate that CYP2D6 is primarily responsible for the metabolism of enclomiphene.<br /><em>CYP2D6 is primarily responsible for the metabolism of clomiphene. Ghobadi C, Gregory A, Crewe HK, Rostami-Hodjegan A, Lennard MS. Drug Metab Pharmacokinet. 2008;23(2):101-5.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clomipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. In addition, clomipramine and desmethylclomipramine are metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clonazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clonidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in form of the unchanged parent drug (40-60% of the dose).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clopidogrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug that is converted to its active metabolites via CYPs 3A4, 2B6, 2C19 and 1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clorazepate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolized to oxazepam by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cloxacillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. About 35% of an oral dose is excreted in the urine and up to 10% in the bile. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete) last reviewed 03/11/11</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Clozapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clozapine is metabolized by CYPs 1A2, 2C19, 3A4, and to a lesser extent by CYPs 2C9 and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cobicistat (with ATV or DRV)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cocaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cocaine is metabolized by several pathways (non CYP and CYP mediated), with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Codeine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as codeine is glucuronidated by several UGTs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Colchicine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as colchicine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Colecalciferol (Vitamin D3)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. There is little potential for interaction with abacavir via modulation of, or competition for, metabolic pathways.  </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cubeb pepper (Piper cubeba)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. There is no evidence to suggest that Piper cubeba impacts UGTs.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cyanocobalamin (Vitamin B12)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cyclophosphamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cycloserine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cycloserine is predominantly excreted renally via glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Cycloserine is excreted into the urine, levels appearing within half an hour of oral ingestion. Approximately 66 per cent of a dose appears unchanged in the urine in 24 hours. A further 10 per cent is excreted over the next 48 hours. It is not significantly excreted in the faeces. Approximately 35 per cent is metabolised, but the metabolites have not yet been identified.<br /><em>Cycloserine UK Summary of Product Characteristics, King Pharmaceuticals Ltd,&nbsp; updated November 2007</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cyproterone acetate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyproterone acetate is metabolized by CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p><hr>





</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Cytarabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cytarabine is metabolized by cytidine deaminase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dabigatran</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dabigatran is not metabolized by CYP450 isoenzymes and is mainly cleared by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dacarbazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dacarbazine undergoes activation to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Daclatasvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as abacavir is metabolised by UGTs. No dose adjustment of daclatasvir or abacavir is required. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dactinomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Results of a study in patients with malignant melanoma indicate that dactinomycin (3H actinomycin D) is minimally metabolized, is concentrated in nucleated cells, and does not penetrate the blood-brain barrier. Approximately 30% of the dose was recovered in urine and feces in one week. The terminal plasma half-life for radioactivity was approximately 36 hours.<br /><em>Cosmegen&#174; (dactinomycin) for Injection US Prescribing Information, Lundbeck, Updated March 2012</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dalteparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but a clinically significant pharmacokinetic interaction is unlikely. Dalteparin is excreted largely unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dapsone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of dapsone is mainly by N-acetylation with a component of N-hydroxylation, and is via multiple CYP P450 enzymes. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Darifenacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darifenacin is metabolized by CYP3A4 and CYP2D6.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Darunavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Based on the different elimination pathways (abacavir metabolism is not mediated by CYP450), no significant interactions are expected with darunavir/ritonavir. Coadministration decreased abacavir AUC, Cmax and Cmin by 27%, 22% and 38%, respectively. However, studies are required to relate the change in plasma abacavir exposure to the active intracellular carbovir triphosphate. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>This interaction has not been studied. Based on the different elimination pathways of the other NRTIs zidovudine, emtricitabine, stavudine, lamivudine, that are primarily renally excreted, and abacavir for which metabolism is not mediated by CYP450, no interactions are expected for these medicinal compounds and darunavir coadministered with low dose ritonavir. <br /><em>Prezista Summary of Product Characteristics, Janssen-Cilag Ltd, <em>February 2011</em>.</em></p>
<p>Based on the different elimination pathways of the NRTIs (zidovudine, zalcitabine, emtricitabine, stavudine, lamivudine and abacavir) that are primarily renally excreted, no drug interactions are expected for these drugs and darunavir/ritonavir. <br /><em>Prezista Prescribing Information, Tibotec Inc, December 2010.</em></p>
<p>The steady-state plasma pharmacokinetics of abacavir (600 mg once daily) were investigated when co-administered with darunavir/ritonavir (900/100 mg once daily) to 19 HIV+ subjects. Abacavir AUC, Cmax and Cmin decreased by 27%, 22% and 38%, respectively in the presence of darunavir/ritonavir. It is important to relate the change in plasma abacavir exposure to the active intracellular carbovir triphosphate and a study is in progress. <br /><em>Pharmacokinetics (PK) of plasma abacavir (ABC) in the absence and in the presence of darunavir/ritonavir (DRV/r) or raltegravir (RAL) in HIV-infected subjects. Jackson A, Gedela K, Dickinson L, et al. 12th European AIDS Conference (EACS), Cologne, November 2009, abstract PE4.3/2.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dasatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.  Dasatinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Daunorubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Daunorubicin hydrochloride is mainly metabolized in the liver; each accompanying medication influencing liver function may also influence the metabolism or pharmacokinetics of daunorubicin hydrochloride and as a consequence influence efficacy and/or toxicity. Daunorubicin is rapidly taken up by tissues, especially by the kidneys, spleen, liver and heart. It does not cross the blood-brain barrier, subsequent release of drug and its metabolites from the tissues is slow (t&#189; = 55 hours). Daunorubicin is rapidly metabolised in the liver. The major metabolite daunorubicinol is also active. Daunorubicin is excreted slowly in the urine, mainly as metabolites with 25% excreted in the first 5 days. Biliary excretion also makes a significant (40%) contribution to elimination. <br /><em>Daunorubicin 20mg Powder for Injection UK Summary of Product Characteristics, Zentiva, updated March 2012</em></p>
<p>The plasma pharmacokinetics of DaunoXome(daunorubicin citrate liposome injection) differ significantly from the results reported for conventional daunorubicin hydrochloride. DaunoXome has a small steady-state volume of distribution of 6.4 L, (probably because it is confined to vascular fluid volume), and clearance of 17 mL/min. These differences in the volume of distribution and clearance result in a higher daunorubicin exposure (in terms of plasma AUC) from DaunoXome than with conventional daunorubicin hydrochloride. The apparent elimination half-life of DaunoXome is 4.4 hours, far shorter than that of daunorubicin, and probably represents a distribution half-life. Daunorubicinol, the major active metabolite of daunorubicin, was detected at low levels in the plasma following intravenous administration of DaunoXome.<br /><em>DaunoXome&#174; (daunorubicin citrate liposome injection) US Prescribing Information, Galen Limited, updated December 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Delavirdine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Denosumab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Denosumab is not eliminated via hepatic metabolism but follows the immunoglobulin clearance pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Desflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desflurane is almost exclusively eliminated unchanged by the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Desipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as desipramine is metabolized by CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Desogestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possible CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dexamethasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexamethasone is metabolized mainly in the liver but also in the kidney. Dexamethasone and its metabolites are excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dexmedetomidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexmedetomidine undergoes extensive hepatic metabolism through direct glucuronidation (mainly via UGT1A4, 2B10) and cytochrome P450 (mainly CYP2A6). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dextropropoxyphene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dextropropoxyphene is mainly metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Diamorphine (diacetylmorphine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Diazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized to nordiazepam (by CYP3A4 and 2C19) and to temazepam (mainly by CYP3A4). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Diclofenac</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidized by CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Didanosine (ddI)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Diethylcarbamazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning the metabolism/elimination and toxicity profile of diethylcarbamazine, there is little potential for interaction with abacavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Diethylcarbamazine is readily absorbed from the gastrointestinal tract and also through the skin and conjunctiva. It is widely distributed in tissues and is mainly excreted in the urine unchanged and as the N-oxide metabolite. Urinary excretion and hence plasma half-life is dependent on urinary pH. About 5% of a dose is eliminated in the faeces. Results in patients with chronic renal impairment and in healthy subjects, given a single 50-mg oral dose of diethylcarbamazine citrate, indicated that the plasma half-life of diethylcarbamazine is prolonged and its 24-hour urinary excretion considerably reduced in those with moderate and severe degrees of renal impairment<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011 </em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Digoxin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Digoxin is eliminated unchanged in the kidney via the renal transporters OATP4C1 and P-gp.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dihydrocodeine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely in the range of observed clinical concentrations as dihydrocodeine is glucuronidated by UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dihydroergotamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as dihydroergotamine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Diloxanide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Diloxanide furoate is largely hydrolysed under the combined action of bacterial and gut esterases and consequently glucuronidated. No clinically-significant drug interactions are known, and significant interactions with antiretrovirals are unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>In the gut, diloxanide furoate is largely, if not wholly, hydrolysed into diloxanide and furoic acid under the combined action of bacterial and gut esterases. After absorption, diloxanide is very rapidly conjugated to form a glucuronide. In circulating blood, it is present to about 99% as a glucuronide and 1% as free diloxanide. Diloxanide is predominantly excreted in the urine. It is believed that the unabsorbed diloxanide is the active anti-amoebic substance, up to 10% remaining in the gut which is subsequently excreted as diloxanide in the faeces. No clinically-significant drug interactions are known<br /><em>Diloxanide Tablets 500mg UK Summary of Product Characteristics, Sovereign Medical, updated September 2007</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Diltiazem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as diltiazem is metabolized by CYP3A4 and CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Diphenhydramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dipyridamole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Disopyramide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Disopyramide is metabolized by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Disulfiram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase abacavir concentrations due to inhibition of alcohol dehydrogenase by disulfiram.  No a priori dosage adjustment is required as abacavir has a large therapeutic index.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Docetaxel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as docetaxel is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dolasetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dolutegravir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Domperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as domperidone is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dopamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. There is little potential for dopamine to affect disposition of antiretrovirals, or to be affected if co-administered with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Orally administered dopamine is rapidly metabolised in the G.I. tract. Following IV administration, the onset of action of dopamine occurs within 5 minutes, and the drug has a duration of action of less than 10 minutes. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-0-methyltransferase to the inactive compounds homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. Dopamine is excreted in urine principally as HVA and its sulphate and glucuroide conjugates and as 3,4-dihydroxyphenylacetic acid. A very small fraction of a dose is excreted unchanged. <br /><em>Dopamine 40 mg/ml Sterile Concentrate UK Summary of Product Characteristics, Hospira UK Ltd, updated August 2010</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Doxazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as doxazosin is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Doxepin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized mainly by CYP2C19 to nordoxepin, an active metabolite. In addition, doxepin and nordoxepin are metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Doxorubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Doxycycline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. No significant metabolism of doxycycline occurs, it is cleared intact by renal and biliary mechanisms.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Doxycycline is almost completely absorbed and is not subject to presystemic metabolism, the mean bioavailability being approximately 93%. No significant metabolism occurs and Doxycycline is cleared intact by renal and biliary mechanisms. Studies to date have indicated that administration of doxycycline at the usual recommended doses does not lead to excessive accumulation of the antibiotic in patients with renal impairment.<br /><em>Doxycycline Capsules BP 100mg, UK Summary of Product Characteristics, Actavis UK Ltd, updated June 2011</em></p>
<p>Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40% and 60% of an administered dose can be accounted for in the urine by 92 hours, and approximately 30% in the faeces. <br /><em>Efracea&#174; 40mg Modified Release Hard Capsules, Summary of Product Characteristics, Galderma (U.K) Ltd, updated November 2011<br />Oracea&#174; US Prescribing Information, Galderma Laboratories, US Prescribing Information, updated May 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Droloxifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as droloxifene is mainly glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dronabinol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolized by CYP2C9 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Drospirenone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Duloxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dutasteride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dutasteride is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Dydrogesterone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Echinacea</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Edoxaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is minimally metabolised by hydrolysis (mediated by carboxylesterase 1), conjugation, or oxidation by CYP3A4/5 (&lt;10%). Edoxaban is eliminated primarily as unchanged drug in urine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Efavirenz</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Specific interaction studies have not been performed with efavirenz and abacavir. Clinically significant interactions would not be expected with abacavir since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways. Abacavir had no effect on efavirenz pharmacokinetics when abacavir, efavirenz and indinavir were coadministered. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have not been performed with efavirenz and NRTIs other than lamivudine, zidovudine, and tenofovir disoproxil fumarate. Clinically significant interactions are not expected since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways. No dosage adjustment is necessary for either medicinal product. <br /><em>Sustiva Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, April 2015.<br />Sustiva Prescribing Information, Bristol-Myers Squibb Company, March 2015.</em></p>
<p>The effect of abacavir (300 mg twice daily) on the pharmacokinetics of indinavir was assessed in HIV+ subjects receiving indinavir 1000 mg three times daily with efavirenz 600 mg once daily, or indinavir/efavirenz 1200/300 mg twice daily. Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. <br /><em>Indinavir, efavirenz and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. DiCenzo R, Forrest A, Squires KE, et al. Antimicrob Agents Chemother, 2003, 47: 1929-1935. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Eflornithine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Eflornithine is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>After intravenous doses about 80% is excreted unchanged in the urine in 24 hours. The terminal elimination half-life is about 3 hours. It is distributed to the CSF. <br />Less than 1% of a dose is absorbed after topical application. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 23-Sep-2011</em></p>
<p>Eflornithine was administered to six healthy men in single intravenous doses of 5 and 10 mg/kg and oral doses of 10 and 20 mg/kg. Peak plasma concentrations were reached within 6 hr after oral doses. The decay of the plasma concentrations followed first-order kinetics with a mean half-life (t 1/2) for all four doses studied of 199 +/- 6 min (+/- SD). Mean renal clearance was determined as 0.99 +/- 0.03 ml . min-1 . kg-1, accounting for 83% of drug elimination. Mean apparent volume of distribution (aVD) was 0.337 +/- 0.031 l/kg-1, corresponding to 24 l for 70 kg of body weight. The amount of unchanged drug in 24-hr urine samples was 47 +/- 7% and 40 +/- 11% after 10 and 20 mg/kg orally, and 78% and 81 +/- 8% after 5 and 10 mg/kg intravenously. Twenty-four-hour urinary recovery of unchanged drug was 46.9% of the 10mg/kg and 40.3% of the 20 mg/kg oral doses. &gt;86% of the oral doses were cleared from the body by renal filtration. In the case of intravenous dosing, 81% of the drug was eliminated by the kidneys. <br /><em>Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Haegele KD, Alken RG, Grove J et al. Clin Pharmacol Ther. 1981 Aug;30(2):210-7.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Elbasvir/Grazoprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Abacavir is metabolised by UGT, which is not expected to be affected by elbasvir/grazoprevir, and is renally cleared. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Eltrombopag </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (UGTs 1A1 and 1A3) and oxidation (CYPs 1A2 and 2C8).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Elvitegravir/Cobi/FTC/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div><div><div>Genvoya should not be co-administered with other antiretroviral medicinal products. <br /><em>Genvoya Summary of Product Characteristics, Gilead Sciences International Ltd, November 2015.</em></div><br /></div><div>Genvoya  is a complete regimen for the treatment of HIV-1 infection;  therefore,  coadministration of Genvoya with other antiretroviral  medications for  treatment of HIV-1 infection should be avoided.</div><div><em>Genvoya US Prescribing Information, Gilead Sciences Inc, November 2015.</em></div></div><em></em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Elvitegravir/Cobi/FTC/TDF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Stribild is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div> <div>Stribild is indicated for use as a complete regimen for the  treatment of HIV 1 infection and must not be administered with other  antiretroviral products.<br /><em>Stribild Summary of Product Characteristics, Gilead Sciences International Ltd, May 2015.</em><br /><br /></div><div>Stribild  is a complete regimen for the treatment of HIV-1 infection; therefore,  Stribild should not be administered with other antiretroviral  medications for treatment of HIV-1 infection.</div><div><em>Stribild Prescribing Information, Gilead Sciences Inc, July 2015.</em></div><div>&nbsp;</div><div>Healthy  volunteers (n=24) were administered a single dose of abacavir (600 mg)  and elvitegravir/ritonavir (200/100 mg once daily) alone and in  combination. Elvitegravir/ritonavir did not have significant effects on  the kinetics of abacavir (AUC decreased by 16%, Cmax decreased by 12%).  Elvitegravir AUC and Cmax decreased by 3% and 5%, with Cmin increasing  by 6%.<div><em>Pharmacokinetics of coadministered ritonavir-boosted  elvitegravir and  zidovudine, didanosine, stavudine, or abacavir.  Ramanathan S, Shen G,  Hinkle J, et al. J Acquir Immune Defic Syndr,  2007, 46(2):160-6.</em></div></div> </div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Empagliflozin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is mainly glucuronidated by UGTs 1A3, 1A8, 1A9 and 2B7. It is a substrate of P-gp and BCRP, and also a substrate of the renal transporter OAT3 and the hepatic transporters OATP1B1 and OATP1B3.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Emtricitabine (FTC)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Emtricitabine/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. A high rate of virological failure and emergence of resistance have been reported with once daily regimens of abacavir with lamivudine and tenofovir-DF; the same problems may be seen if Descovy is administered with a third nucleoside analogue.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when tenofovir disoproxil fumarate was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen. Therefore, the same problems may be seen if Descovy is administered with a third nucleoside analogue.<br><em>Descovy Summary of Product Characteristics, Gilead Sciences Ltd, April 2016.</em></p>

</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Enalapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.  Enalapril is hydrolysed to enalaprilat which is eliminated renally, possibly via OATs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Enflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as enflurane is predominantly metabolized by CYP2E1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Enfuvirtide (T20)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Enoxaparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is excreted predominantly renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Entecavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anion and cation transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ephedrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ephedrine is predominantly eliminated unchanged via the kidneys .</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Ephedrine is rapidly and completely absorbed after oral administration and extensively distributed throughout the body with accumulation in the liver, lungs, kidneys, spleen and brain. The plasma half-life is reported to be between 3-11 hours, with up to 95% being excreted in the urine.<br /><em>Ephedrine Hydrochloride Tablets UK Summary of Product Characteristics, Wockhardt UK Ltd, updated November 2008</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Epirubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as epirubicin is glucuronidated by UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Eprosartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as eprosartan is largely excreted in bile and urine as unchanged drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ergometrine (Ergonovine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Ergometrine is extensively metabolized, most likely by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ergotamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Ergotamine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Erlotinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Erlotinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ertapenem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied significant drug interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor role.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Erythromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Erythromycin is extensively metabolized in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Escitalopram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Esomeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as esomeprazole is mainly metabolized by CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Estazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Estradiol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as estradiol is metabolized by CYP1A2 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Estramustine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estramustine phosphate undergoes rapid dephosphorylation to estramustine which is then oxidized by 17beta-hydroxysteroid dehydrogenases to estromustine. Estramustine and estromustine are subsequently hydrolyzed to estradiol and estrone, respectively. Estradiol is then hydroxylated by CYPs 1A1, 1A2 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ethambutol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and in the urine (50%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ethinylestradiol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethinylestradiol is mainly metabolized by hydroxylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ethionamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ethionamide is extensively metabolized in the liver, animal studies suggest involvement of flavin-containing monooxygenases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ethionamide is extensively metabolized to active and inactive metabolites. Metabolism is presumed to occur in the liver and 6 metabolites have been isolated: 2-ethylisonicotinamide, carbonyl-dihydropyridine, thiocarbonyl-dihydropyridine, S-oxocarbamoyl dihydropyridine, 2-ethylthioiso-nicotinamide, and ethionamide sulphoxide. The sulphoxide metabolite has been demonstrated to have antimicrobial activity against Mycobacterium tuberculosis. Less than 1% of the oral dose is excreted as ethionamide in urine.<br /><em>Trecator&#174; US Prescribing Information, Wyeth Pharmaceuticals Inc. (now Pfizer) revised November 2007</em></p>
<p>An in vitro study examined the inhibitory effects of pyrazinamide and ethionamide, both of which are chemically related to isoniazid, on the CYP-mediated activities in human liver microsomes and compared them to that of isoniazid. No remarkable effects on any CYP activities were observed by pyrazinamide and ethionamide.<br /><em>Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. Nishimura Y, Kurata N, Sakurai E, Yasuhara H. J Pharmacol Sci. 2004 Nov;96(3):293-300.</em></p>
<p>Flavin-containing monooxygenases (FMOs) are a superfamily of flavoprotein monooxygenases active towards a wide range of xenobiotics. ethionamide (ETA) is a pro-drug requiring bioactivation to exert toxicity. M. tuberculosis possesses a flavin monooxygenase (EtaA) that oxygenates ETA first to the sulfoxide and then to 2-ethyl-4-amidopyridine, presumably through a second oxygenation involving sulfinic acid. ETA is also a substrate for mammalian flavincontaining monooxygenases (FMOs). A study examined activity of expressed human and mouse FMOs toward ETA, as well as liver and lung microsomes. All FMOs converted ETA to the S-oxide (ETASO), the first step in bioactivation. Co-incubations with the general CYP and FMO inhibitors SKF-525A and thiourea, suggest that ETA S-oxygenation in mouse liver and lung microsomes is predominantly, FMO-mediated.<br /><em>Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Henderson MC, Siddens LK, Morr&#233; JT, et al. Toxicol Appl Pharmacol. 2008 Dec 15;233(3):420-7</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ethosuximide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ethosuximide is mainly oxidized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Etonogestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel undergoes hepatic metabolism by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Etoposide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etoposide is partly glucuronidated by UGT1A1 and partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Etravirine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but no interaction is expected. Etravirine can be used without dose adjustment. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration has not been studied, but no interaction is expected based on the primary renal elimination route for abacavir, emtricitabine, lamivudine, stavudine and zidovudine. Etravirine can be used with these NRTIs without dose adjustment. <br /><em>Intelence Summary of Product Characteristics, Janssen-Cilag Ltd, March 2012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Eucalpytus globulus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. There is no evidence to suggest that eucalyptus&nbsp;impacts UGTs.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Everolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.  Everolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Exemestane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exemestane is metabolized by CYP3A4 and aldoketoreductase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Exenatide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as exenatide is primarily eliminated by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>&nbsp;(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ezetimibe</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Famciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famciclovir is converted to penciclovir by aldehyde oxidase. Penciclovir is secreted in the urine possibly by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Famotidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famotidine is eliminated by renal excretion via OAT3 (65-70%) and by metabolic routes (30-35%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Felodipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as felodipine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fenofibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolyzed to an active metabolite, fenofibric acid.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fentanyl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fesoterodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fesoterodine is rapidly hydrolysed to its active metabolite which is subsequently metabolized by CYP2D6 and CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fexofenadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine undergoes negligible metabolism and is mainly eliminated unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Finasteride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Finasteride is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fish oils</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Flecainide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolized mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Flibanserin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flibanserin is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Flucloxacillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as flucloxacillin is mainly eliminated renally. However, HLA-5701 has been identified as the main genetic risk factor for flucloxacillin induced liver injury and patients should be genotyped before receiving either drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fluconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluconazole is mainly eliminated renally by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Flucytosine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucytosine is metabolised to 5-flurouracil which is further metabolised by dihydropyrimidine dehydrogenase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fludarabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludarabine phosphate is rapidly hydrolyzed (non-CYP mediated) to 2F-ara-A, the principal metabolite, which is then eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fludrocortisone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Flunitrazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolized mainly via CYP3A4 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fluocinolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely with the topical use of fluocinolone.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fluorouracil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Fluorouracil is metabolised via the same mechanisms as endogenous uracil, including via dihydropyrimidine dehydrogenase. There is therefore little potential for interaction with abacavir via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Following IV administration, the plasma elimination half-life averages about 16 minutes and is dose dependant. Following a single intravenous dose of Fluorouracil approximately 15% of the dose is excreted unchanged in the urine within 6 hours; over 90% of this is excreted in the first hour. The remainder is mostly metabolised in the liver by the usual body mechanisms for uracil.<br /><em>Fluorouracil 50 mg/ml Injection UK Summary of product Characteristics, Hospira UK Ltd, updated August 2011<br />Adrucil&#174; (Fluorouracil injection USP) US Prescribing Information, Teva ParenteralMedicines Inc, Issued July 2007</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fluoxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYPs 2D6 and 2C9 and to a lesser extent by 2C19 and 3A4 to form norfluoxetine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fluphenazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Fluphenazine is predominantly metabolised via CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Fluphenazine is metabolised by P450 2D6 and is itself an inhibitor of this drug metabolising enzyme. The plasma concentrations and the effects of fluphenazine may therefore be increased and prolonged by drugs that are either the substrates or inhibitors of this P450 isoform, possibly resulting in severe hypotension, cardiac arrhythmias or CNS side effects.<br /><em>Modecate&#174; (fluphenazine) Concentrate Injection 100mg/ml UK Summary of product Characteristics, sanofi-aventis, updated December 2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Flurazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as the metabolism of flurazepam is most likely CYP-mediated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fluticasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as fluticasone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fluvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as fluvastatin is metabolised mainly by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fluvoxamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Folic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fondaparinux</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is eliminated predominantly renally.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Formestane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Formoterol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. As multiple CYP450 and UGT enzymes catalyze the transformation the potential for a pharmacokinetic interaction is low.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Fosamprenavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No data with fosamprenavir/ritonavir. Coadministration with amprenavir alone had no effect on abacavir or amprenavir pharmacokinetics. Based on these results and because ritonavir is not expected to have a significant impact on the pharmacokinetics of NRTI, no significant interaction is expected with fosamprenavir/ritonavir. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Interaction studies with abacavir have been performed with amprenavir without ritonavir. No studies have been performed with fosamprenavir/ritonavir. No clinically significant interaction is expected and no dosage adjustment is necessary.&nbsp; <br /><em>Telzir Summary of Product Characteristics, ViiV Healthcare UK Ltd, May 2011. </em></p>
<p>Coadministration of amprenavir (900 mg twice daily) and abacavir (300 mg twice daily) was studied in 4 subjects. When compared with a parallel control group there was change in amprenavir or abacavir AUC, Cmax or Cmin. <br /><em>Lexiva Prescribing Information, ViiV Healthcare, April 2012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Foscarnet</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as foscarnet is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Furosemide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Gabapentin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant interaction is unlikely as gabapentin is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Gamma-hydroxybutyrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant interaction is unlikely. Gamma-hydroxybutyrate undergoes first pass metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ganciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ganciclovir is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Garlic</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although garlic has been shown to induce intestinal CYP3A4 and/or P-gp, this is not expected to impact abacavir exposure.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Gefitinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.  Gefitinib is metabolized by CYP3A4 and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Gemcitabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemcitabine is metabolized in the liver by cytidine deaminase to an inactive metabolite.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Gemfibrozil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as gemfibrozil is metabolised mainly by UGT2B7. Although abacavir is partly glucuronidated, an interaction due to competition for glucuronidation is unlikely since several UGTs are involved in gemfibrozil metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Gentamicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Gentamicin is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Gentamicin is not metabolized in the body but is excreted unchanged in microbiologically active form predominantly via the kidneys.<br /><em>Gentamicin 40 mg/ml Injection Summary of Product Characteristics, Hospira UK Ltd, updated August 2011</em></p>
<p>Little, if any, metabolic transformation occurs; the drug is excreted principally by glomerular filtration.&nbsp; After several days of treatment, the amount of gentamicin excreted in the urine approaches, but does not equal, the daily dose administered.&nbsp; As with other aminoglycosides, a small amount of the gentamicin dose may be retained in the tissues, especially in the kidneys.&nbsp; Minute quantities of aminoglycosides have been detected in the urine of some patients weeks after drug administration was discontinued.&nbsp; Renal clearance of gentamicin is similar to that of endogenous creatinine. Probenecid does not affect renal tubular transport of gentamicin.<br /><em>Gentamicin Injection USP, US Prescribing Information, APP Pharmaceuticals, revised August 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Gestodene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ginger (Zingiber officinale)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. There is no evidence to suggest that ginger inhibits or induces UGTs.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ginkgo biloba</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Glibenclamide (Glyburide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Gliclazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as gliclazide is metabolised by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Glimepiride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as glimepiride is metabolised by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Glipizide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as glipizide is mainly metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Goldenseal root (Hydrastis canadensis)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Goserelin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Goserelin is mainly hydrolyzed.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Granisetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as granisetron is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Grapefruit juice</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although grapefruit juice inhibits CYP3A4, this is not expected to alter exposure of abacavir as its metabolism is not CYP-mediated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Griseofulvin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Griseofulvin undergoes glucuronidation, although this is not the sole route of metabolism. There is little potential for interactions via competition of griseofulvin with abacavir for glucuronidation pathways. In vitro studies using rat liver microsomes have shown that griseofulvin can inhibit glucuronidation of some substances, however the UGT isoforms affected are not known. As abacavir is also metabolised via alcohol dehydrogenase, there is little potential for clinically significant interaction</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Griseofulvin undergoes metabolism to inactive metabolites, principally 6-desmethylgriseofulvin or its glucuronide conjugate, the majority of which are excreted in the urine, with less than 1% of the administered dose being excreted as unchanged drug. The remainder of the dose, principally as metabolites, is excreted in bile and faeces. <br /><em>Griseofulvin 500mg Tablets Summary of Product Characteristics, Morningside Healthcare Ltd, May 2010</em></p>
<p>Eight toxic compounds of natural origin present in the human diet or used as drugs were tested as inhibitors of UDP-glucuronosyltransferase (UGT) activity in rat liver microsomes with 1-naphthol (1-NA), phenolphthalein (PPh) and 4-nitrophenol (4-NP) as substrates. Strong inhibitory effects were observed with the antifungal drug griseofulvin (GF): at a concentration of 1 mM, GF completely suppressed the glucuronidation of 1-NA and PPh, respectively. A concentration of 0.1 mM still proved to be highly inhibitory. The inhibition by GF was non-competitive with respect to PPh and was of a mixed type toward UDP-glucuronic acid, with apparent Ki values of 40 microM and 30 microM, respectively. GF did not act as a substrate for rat microsomal UGT.<br /><em>Grancharov K, Engelberg H, Naydenova Z, et al. Inhibition of UDP-glucuronosyltransferases in rat liver microsomes by natural mutagens and carcinogens. Arch Toxicol. 2001 Dec;75(10):609-12.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Halofantrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halofantrine is extensively metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Haloperidol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol undergoes glucuronidation (UGT2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, 2D6).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Halothane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halothane undergoes both oxidative and reductive metabolism by cytochromes. In vitro data have shown that oxidation occurs mainly via CYP2E1 and to a lesser extent CYP2A6 and reduction via CYP2A6 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Heparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Heparin is thought to be eliminated via the reticuloendothelial system.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>After intravenous or subcutaneous injection heparin is extensively bound to plasma proteins. The half-life of heparin depends on its dose and route as well as the method of calculation and is subject to wide inter- and intra-individual variation; a range of 1 to 6 hours with an average of 1.5 hours has been cited. It may be slightly prolonged in renal impairment, decreased in patients with pulmonary embolism, and either increased or decreased in patients with liver disorders. Heparin is taken up by the reticuloendothelial system. It is excreted in the urine, mainly as metabolites, although after large doses up to 50% may be excreted unchanged.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last reviewed 2011-11-15</em></p>
<p>Heparin is not eliminated enzymatically nor by glomerular filtration or renal tubular secretion. In all likelihood, the anticoagulant is transferred to reticuloendothelial cells, which may also provide the means for its degradation.<br /><em>Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204&#8211;20.</em></p>
<p>After either subcutaneous or intravenous injection heparin is distributed primarily within the intravascular space. A short distribution phase is seen which is thought to correspond to endothelial cell binding and internalisation. The disposition curve for unfractionated heparin has a unique concave-convex shape which is the result of combined saturable and nonsaturable elimination mechanisms. The nonsaturable elimination mechanism is renal and is the primary route of elimination for low molecular weight heparins.<br /><em>Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22: 359&#8211;74.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Heroin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically relevant drug interaction is unlikely. When used illicitly, heroin is mainly injected or inhaled through the nose and goes directly in the bloodstream. Heroin is then rapidly deacetylated to 6-monoacetylmorhine (6-MAM) and subsequently to morphine by plasma and liver esterase, respectively. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Abacavir does not affect these metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Hops (Humulus lupulus)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that extracts of hops activate PXR and thereby induce the expression of CYP3A4, CYP2B6 and MDR1. However, this is not expected to alter exposure of abacavir as its metabolism is not CYP-mediated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Hydralazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Hydralazine is metabolised via primary oxidative metabolism and acetylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Hydralazine is rapidly absorbed from the gastrointestinal tract and peak plasma concentrations have been reported to occur in the plasma after about one hour. It is metabolised by hydroxylation of the ring system and conjugation with glucuronic acid, and by N-acetylation.<br /><em>Hydralazine Tablets BP 50mg UK Summary of Product Characteristics, Actavis UK Ltd, updated April 2011</em></p>
<p>Hydralazine is rapidly absorbed after oral administration, and peak plasma levels are reached at 1 to 2 hours. Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours. Binding to human plasma protein is 87%. Plasma levels of hydralazine vary widely among individuals. Hydralazine is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of blood pressure. Hydralazine undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.<br /><em>Hydralazine hydrochloride tablets USP US Prescribing Information, TEVA Pharmaceuticals USA, updated March 2012</em></p>
<p>Pharmacokinetic data indicate hydralazine is absorbed well from the gastrointestinal tract, and has an extensive and complex metabolism depending on acetylator status: slow acetylators undergo primary oxidative metabolism, while rapid acetylators are acetylated.<br /><em>Mulrow JP, Crawford MH. Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure. Clin Pharmacokinet. 1989 Feb;16(2):86-9</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Hydrochlorothiazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised and is cleared by the kidneys via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Hydrocodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Hydrocortisone (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Hydrocortisone (topical)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but no clinically relevant drug interactions are expected with the topical use of hydrocortisone.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Hydromorphone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Hydroxyurea (Hydroxycarbamide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However, hydroxyurea is not licensed for use in combination with stavudine and didanosine as toxicities including pancreatitis and hepatitis (in some cases fatal) in HIV patients have been reported via post marketing surveillance. Thus, caution and monitoring for side effects is recommended if coadministered with other NRTIs such as abacavir.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Hydroxyzine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ibandronic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary) </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ibuprofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ifosfamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for pharmacokinetic interaction. Ifosfamide is predominantly metabolized by CYP3A4 and CYP2B6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The pharmacokinetics of ifosfamide exhibit considerable interindividual variation. It is a prodrug that is extensively metabolised, chiefly by cytochrome P450 isoenzymes such as CYP3A4 and CYP2B6 in the liver, to both active and inactive metabolites; there is some evidence that metabolism is saturated at very high doses. Although licensed product information states that a mean terminal elimination half-life is about 15 hours after a single high-dose intravenous bolus, most studies at lower doses recorded elimination half-lives of 4 to 8 hours. After repeated doses there is a decrease in the elimination half-life, apparently due to autoinduction of metabolism. It is excreted largely in urine, as unchanged drug and metabolites. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 20-Aug-2010<br />Wagner T. Clin Pharmacokinet 1994; 26: 439&#8211;56; Boddy AV, Yule SM. Clin Pharmacokinet 2000; 38: 291&#8211;304; Kerbusch T, et al. Clin Pharmacokinet 2001; 40: 41&#8211;62.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Iloperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Iloperidone is metabolised by CYP3A4 and CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Imatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imatinib is primarily metabolized by CYP3A4 and to a lesser extent by CYPs 1A2, 2D6, 2C9 and 2C19. In vitro data indicate that imatinib inhibits CYPs 3A4, 2D6, 2C9 and 2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Imipenem/Cilastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal clearance of unchanged drug occurs via glomerular filtration and to a lesser extent, active tubular secretion for both imipenem (when administered with cliastatin), and cilastatin.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>When administered alone, imipenem is metabolised in the kidneys by dehydropeptidase-I. Individual urinary recoveries ranged from 5 to 40%, with an average recovery of 15-20% in several studies. Cilastatin is a specific inhibitor of dehydropeptidase-I enzyme and effectively inhibits metabolism of imipenem so that concomitant administration of imipenem and cilastatin allows therapeutic antibacterial levels of imipenem to be attained in both urine and plasma.<br />Approximately 70% of the administered antibiotic was recovered intact in the urine within ten hours, and no further urinary excretion of imipenem was detectable. Urine concentrations of imipenem exceeded 10 &#956;g/ml for up to eight hours after a 500 mg/500 mg dose of imipenem/cilastatin. The remainder of the administered dose was recovered in the urine as antibacterially inactive metabolites, and faecal elimination of imipenem was essentially nil.<br /><em>Primaxin&#174; IV Injection Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated October 2011<br />Primaxin&#174; I.V. (Imipenem and cilastatin for injection) US Prescribing Information, Merck&amp;Co Inc, Issued February 2010</em><br /><br />Approximately 70-80% of the dose of cilastatin was recovered unchanged in the urine as cilastatin within 10 hours of administration of imipenem/cilastatin. No further cilastatin appeared in the urine thereafter. Approximately 10% was found as the N-acetyl metabolite, which has inhibitory activity against dehydropeptidase comparable to that of cilastatin. Activity of dehydropeptidase-I in the kidney returned to normal levels shortly after the elimination of cilastatin from the blood stream.<br /><em>Primaxin&#174; IV Injection Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated October 2011<br />Primaxin&#174; I.V. (Imipenem and cilastatin for injection) US Prescribing Information, Merck&amp;Co Inc, Issued February 2010</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Imipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Indapamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolized by CYP P450. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Indinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No data with indinavir/ritonavir. Coadministration with indinavir alone to HIV+ subjects showed that abacavir had no significant effect on indinavir concentrations. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The effect of abacavir (300 mg twice daily) on the pharmacokinetics of indinavir and efavirenz was assessed in HIV+ subjects receiving indinavir 1000 mg three times daily with efavirenz 600 mg once daily, or indinavir/efavirenz 1200/300 mg twice daily. Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. <br /><em>Indinavir, efavirenz and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. DiCenzo R, et al. Antimicrob Agents Chemother, 2003, 47: 1929-1935.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Insulin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Interferon alpha</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Hepatic decompensation (some fatal) has occurred in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia. Some data suggest that HIV/HCV co-infected patients receiving abacavir-containing ART may be at risk of a lower response rate to pegylated interferon/ribavirin therapy although this has not been confirmed in other studies.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Interleukin 2 (Aldesleukin)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as interleukin-2 is mainly eliminated by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Inula racemosa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. There are no indications that Inula racemosa impacts UGTs or P-gp.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Iodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva.<br /><em>Aqueous Iodine Oral Solution BP UK Summary of Product Characteristics, Thornton &amp; Ross Ltd, updated November 2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ipratropium bromide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. A small proportion of an inhaled ipratropium dose is systemically absorbed (6.9%). Metabolism is via ester hydrolysis and conjugation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>After intravenous administration approximately 60% of the dose is metabolised, mainly by conjugation (40%), wheras after inhalation about 77% of the systemically available dose is metabolised by ester hydrolysis (41%) and conjugation (36%). After inhalation of ipratropium bromide either with HFA 134a or CFC propellant, cumulative renal excretion over 24 hours was approximately 12% and 10%, respectively.&nbsp; In an excretion balance study cumulative renal excretion (6 days) of drug-related radioactivity (including parent compound and all metabolites) accounted for 72.1% after intravenous administration, 9.3% after oral administration and 3.2% after inhalation. The main urinary metabolites bind poorly to the muscarinic receptor and have to be regarded as ineffective.<br /><em>Atrovent&#174; (Ipratropium bromide) 20 micrograms/actuation Inhaler CFC-Free UK Summary of Product Characteristics, Boehringer Ingelheim Limited, updated August 2011</em></p>
<p>After inhalation, around 10 to 30% of a dose is deposited in the lungs where it exerts its therapeutic effect. Only a small amount of ipratropium reaches the systemic circulation. The majority of a dose is swallowed but is poorly absorbed from the gastrointestinal tract. Following oral administration, the apparent systemic availability was around 2%, and after inhalation it was 6.9%. Ipratropium and its metabolites are eliminated in the urine and faeces.<br /><em>Ensing K, et al. Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Eur J Clin Pharmacol 1989; 36: 189&#8211;94.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Irbesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as glucuronidation is not the major contributor of irbesartan clearance.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Irinotecan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as irinotecan is glucuronidated by several UGTs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Iron supplements</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Isoflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as isoflurane is almost exclusively eliminated unchanged by the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Isoniazid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Isosorbide dinitrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Isosorbide dinitrate undergoes extensive first past metabolism, predominantly in the liver, with less than 30% of a dose undergoing subsequent glucuronidation. There is therefore little potential for clinically significant interaction with abacavir via competition for glucuronidation pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Isosorbide dinitrate is readiliy absorbed from the oral mucosa and also following oral administration. It undergoes extensive first pass metabolism, mainly in the liver. <br /><em>Isosorbide Dinitrate Tablets BP 20mg UK Summary of Product Characteristics, Actavis UK Ltd, updated October 2011</em></p>
<p>Isosorbide dinitrate (ISDN) is eliminated from plasma with a short half-life (about 0.7h). The metabolic degradation of ISDN occurs via denitration and glucuronidation, like all organic nitrates. The rate of formation of the metabolites has been calculated for isosorbide-5-mononitrate (IS-5-MN) with 0.27 h -1, and isosorbide (IS) with 0.16 h-1. IS-5-MN and IS-2-MN are the primary metabolites which are also pharmacologically active. IS-5-MN is metabolised to isosorbide 5-mononitrate-2-glucuronide (IS-5-MN-2-GLU). The half-life of this metabolite (about 2.5h) is shorter than that of IS-5-MN (about 5.1h). The half-life of ISDN is the shortest of all and that of IS-2-MN (about 3.2h) lies in between. <br /><em>Isoket&#174; (Isosorbide dinitrate) 1mg/ml injection/infusion UK Summary of Product Characteristics, UCB Pharma Limited, updated July 2010</em></p>
<p>The bioavailabilities of a conventional and two slow release 20 mg isosorbide dinitrate (ISDN) formulations were compared after oral administration in a three way cross-over study in 8 male volunteers. In a further group of 6 male volunteers the pharmacokinetics and metabolism of ISDN were investigated after intravenous infusion of a median dose of 14.1 mg for 2.5 h. The median elimination half-lives of ISDN, IS-5-MN, IS-2-MN and IS-5-MN-2-Glu were 0.7, 5.1, 3.2 and 2.5 h, respectively. Apart from IS-5-MN-2-Glu, with a renal clearance of 5.9 l/min which suggested substantial glucuronidation in the kidney, the renal clearances of ISDN, IS-5-MN, IS-2-MN and the corresponding amounts excreted were negligible. 27.8% of the administered ISDN was excreted as IS-5-MN-2-Glu (8.7%) and IS (19.1%). Calculations based on the two mononitrate metabolites formed from ISDN showed an incomplete recovery of 84.1%, leading to the assumption that a simultaneous denitration to IS must have occurred. <br /><em>Abshagen U, Betzien G, Endele R et al. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Eur J Clin Pharmacol. 1985;27(6):637-44.</em><br /></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Isotretinoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Itraconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as itraconazole is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ivabradine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction as ivabradine is metabolised by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ivermectin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. In vitro studies suggest that ivermectin is predominantly metabolised by CYP3A4, whereas abacavir is metabolised via alcohol dehydrogenase and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Ivermectin is metabolized in the liver, and ivermectin and/or its metabolites are excreted almost exclusively in the feces over an estimated 12 days, with less than 1% of the administered dose excreted in the urine.<br />In vitro studies using human liver microsomes and recombinant CYP450 enzymes have shown that ivermectin is primarily metabolized by CYP3A4. Depending on the in vitro method used, CYP2D6 and CYP2E1 were also shown to be involved in the metabolism of ivermectin but to a significantly lower extent compared to CYP3A4. The findings of in vitro studies using human liver microsomes suggest that clinically relevant concentrations of ivermectin do not significantly inhibit the metabolizing activities of CYP3A4, CYP2D6, CYP2C9, CYP1A2, and CYP2E1.<br /><em>Stromectol&#174; US Prescribing Information, Merck Sharp &amp; Dohme BV Issued May 2010</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Kanamycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Kanamycin is predominantly eliminated unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Kanamycin is rapidly excreted by glomerular filtration and most of a parenteral dose appears unchanged in the urine within 24 hours.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 20-August-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ketamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYP2B6 and CYP2C9 in the range of concentrations used in anaesthesia.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ketoconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as ketoconazole is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Labetalol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lacidipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as lacidipine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lacosamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacosamide is metabolized to O-desmethyl-lacosamide mainly by CYP2C19 (~30% of the dose) and is eliminated unchanged through the kidneys (~40% of the dose).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lactulose</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lamivudine (3TC)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant pharmacokinetic interaction. High rate of virological failure and emergence of resistance reported when lamivudine was combined with tenofovir and abacavir as a once daily regimen. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Clinical studies have shown that there are no clinically significant interactions between abacavir, zidovudine, and lamivudine. <br />Triple NRTI Therapy:<br />There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when abacavir was combined with tenofovir disoproxil fumarate and lamivudine as a once daily regimen. <br /><em>Ziagen Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2011.</em></p>
<p>Due to the common metabolic pathways of abacavir and zidovudine via glucuronyl transferase, 15 HIV-infected patients were enrolled in a crossover study evaluating single doses of abacavir (600 mg), lamivudine (150 mg), and zidovudine (300 mg) alone or in combination. Analysis showed no clinically relevant changes in the pharmacokinetics of abacavir with the addition of lamivudine or zidovudine or the combination of lamivudine and zidovudine. Lamivudine exposure (AUC decreased 15%) and zidovudine exposure (AUC increased 10%) did not show clinically relevant changes with concurrent abacavir. <br /><em>Ziagen Prescribing Information, ViiV Healthcare, May 2012.</em></p>
<p>There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when lamivudine was combined with tenofovir disoproxil fumarate and abacavir as well as with tenofovir disoproxil fumarate and didanosine as a once daily regimen. <br /><em>Epivir Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2010</em></p>
<p>The pharmacokinetics and safety of single doses of abacavir (600 mg), zidovudine (300 mg) and lamivudine (150 mg) were evaluated when given alone or with either or both of the other drugs to 13 HIV-infected subjects. Coadministration of abacavir with lamivudine (with or without zidovudine) decreased lamivudine AUC by ~15%, decreased Cmax by ~ 35% and delayed Tmax by ~1 h. While these changes are statistically significant, they are not considered to be clinically significant. There were no differences in the pharmacokinetics of abacavir when given alone, or with zidovudine or lamivudine, or with both zidovudine and lamivudine. <br /><em>Single dose pharmacokinetics and safety of abacavir (1592U98), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Wang LH, et al. Antimicrob Agents Chemother, 1999, 43: 1708-1715.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lamotrigine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is mainly glucuronidated by UGT1A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lansoprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolized by CYP2C19 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lapatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Lapatinib is metabolized by CYP3A4 and does not significantly inhibit renal transporters (OAT, OCT).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ledipasvir/Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of abacavir (in combination with lamivudine) and ledipasvir/sofosbuvir had no effect on the pharmacokinetic parameters of abacavir, ledipasvir or sofosbuvir. Abacavir Cmax and AUC decreased by 8% and 10%; lamivudine Cmax and AUC decreased by 7% and 6% and Cmin increased by 12%. Ledipasvir Cmax, AUC and Cmin increased by 10%, 18% and 26%; sofosbuvir Cmax and AUC increased by 8% and 21%; AUC and Cmin of GS-331007 increased by 5% and 8% with no change in Cmax. No dose adjustment of ledipasvir/sofosbuvir or abacavir/ lamivudine is required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lercanidipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Letrozole </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolised by CYP3A4 and CYP2A6 to carbinol, an inactive metabolite.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Leuprorelin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Leuprorelin acetate is a peptide that is primarily degraded by peptidases.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Levamisole (Ergamisol)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Metabolism and elimination of levamisole has not been well characterized. Based on limited information, and single dose use of levamisole, clinically significant  interactions are not considered likely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Levamisole is rapidly absorbed from the gastrointestinal tract and peak plasma concentrations occur within 1.5 to 2 hours. It is extensively metabolised in the liver. The plasma half-life for levamisole is 3 to 4 hours and for the metabolites is 16 hours. It is excreted mainly in the urine as metabolites and a small proportion in the faeces. About 70% of a dose is excreted in the urine over 3 days, with about 5% as unchanged levamisole.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Levetiracetam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Levetiracetam undergoes enzymatic hydrolysis (non CYP) and is eliminated unchanged in the urine by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Levocetirizine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Levodopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. In the presence of a peripheral dopa-decarboxylase inhibitor (carbidopa or benserazide) levodopa is metabolised mainly to 3-O-methyldopa by catechol-O-methyltransferase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Levofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as levofloxacin is metabolised to a very small extent.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Levomepromazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as levomepromazine is metabolised by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Levonorgestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is hydroxylated in the liver and the metabolites are excreted as glucuronide conjugates.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Levonorgestrel (Emergency Contraception)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Levothyroxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lidocaine (Lignocaine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Linagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as linagliptin is mainly eliminated as parent compound in faeces. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Linezolid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Linezolid undergoes non-CYP mediated metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Liquorice (Glycyrrhiza glabra)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Liraglutide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as liraglutide is degraded by endogenous endopeptidases. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lisinopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lithium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys and is freely filtered at a rate that is dependent upon the glomerular filtration rate.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Loperamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is mainly metabolized by CYP3A4 and CYP2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p style="margin-bottom: 0cm; line-height: 100%">(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lopinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of abacavir and lopinavir/ritonavir has no effect on lopinavir or ritonavir pharmacokinetics, but appears to decrease abacavir exposure by ~30%. The clinical significance of this is unknown. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Abacavir concentrations may be reduced due to increased glucuronidation by lopinavir. The clinical significance of this reduced abacavir concentrations is unknown.<br /><em>Kaletra Summary of Product Characteristics, Abbott Laboratories Ltd, February 2012.</em></p>
<p>Lopinavir induces glucuronidation and therefore has the potential to reduce abacavir plasma concentrations. The clinical significance of this potential interaction is unknown.<br /><em>Kaletra Prescribing Information, Abbott Laboratories, May 2012.</em></p>
<p>The plasma and intracellular pharmacokinetic interaction between tenofovir and abacavir, lamivudine or lopinavir was investigated in HIV+ subjects receiving TDF + 3TC/LPV (n=7), TDF + 3TC/NVP (n=8), TDF + ABC/LPV (n=7) or TDF + ABC/NVP (n=5). Compared to values when given with nevirapine, abacavir exposure when given with lopinavir was decreased (Cmax by 33%, AUC by 31%). <br /><em>A pharmacokinetic study in HIV infected patients under tenofovir fumarate: investigation of systemic and intracellular interaction between TDF and abacavir, or lamivudine or lopinavir/ritonavir. Pruvost A, et al. 8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, April 2007, abstract 56.</em></p>
<p>Coadministration of abacavir (600 mg once daily) and lopinavir/ritonavir (400/100 mg twice daily) was studied in 12 HIV+ subjects. There was no effect on lopinavir or ritonavir pharmacokinetics, but abacavir AUC decreased by 32% and Cmax decreased by 34%. <br /><em>Abacavir plasma pharmacokinetics in the absence and the presence of atazanavir/ritonavir or lopinavir/ritonavir) and vice versa in HIV+ patients. Waters L, et al. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007, abstract 557.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Loratadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lorazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as lorazepam is mainly glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lormetazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as lormetazepam is mainly glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Losartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as losartan is glucuronidated by several UGTs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lovastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as lovastatin is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lumefantrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as lumefantrine is metabolized predominantly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Lysergic acid diethylamide (LSD)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. LSD (lysergic acid diethylamide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme).</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Macitentan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Magnesium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Magnesium is eliminated in kidney, mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Malabar nut tree (Justicia adhatoda, Adhatoda vasica)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on the limited data available on the effect of malabar nut tree leaf extracts on drug metabolism, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mannitol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Mannitol is metabolised only very slightly, if at all, to glycogen in the liver; it is predominantly eliminated unchanged via glomerular filtration. There is little potential for mannitol to affect the disposition of antiretrovirals, or to be altered if co-administered with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Mannitol is metabolized only very slightly, if at all, to glycogen in the liver. The drug is freely filtered by the glomeruli, with less than 10% tubular reabsorption; it is not secreted by tubular cells. The elimination half-life in adults is about 100 minutes. Approximately 80% of a 100-g dose is excreted unchanged in urine within 3 hours. When large dose are given as in forced diuresis, retention of the drug may occur. In the presence of renal disease in which glomerular function is impaired or in conditions that impair small vessel circulation, such as congestive heart failure, cirrhosis with ascitic accumulation, shock, or dehydration, mannitol clearance is lower than normal.<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, December 2008</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Maprotiline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Maraviroc</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction expected. Maraviroc and NRTIs can be co-administered without dose adjustment. The US Prescribing Information recommends maraviroc should be reduced to 150 mg twice daily in patients with creatinine clearance less than 30 ml/min or on haemodialysis if there are any symptoms of postural hypotension. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>No significant interaction expected. Maraviroc 300 mg twice daily and NRTIs can be co-administered without dose adjustment. <br /><em>Celsentri Summary of Product Characteristics,</em><em>ViiV Healthcare, October 2013</em><em>.</em></p>
<p>The recommended dose of maraviroc when coadministered with NRTIs is 300 mg twice daily. Maraviroc should be reduced to 150 mg twice daily in patients with creatinine clearance &lt;30 ml/min or on haemodialysis if there are any symptoms of postural hypotension.<br /><em>Selzentry Prescribing Information,&nbsp;</em><em>ViiV Healthcare, September 2013</em><em>.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>MDMA (Ecstasy)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. MDMA is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mebendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Orally administered mebendazole is extensively metabolized primarily by the liver. Plasma concentrations of its major metabolites (amino and hydroxylated amino forms of mebendazole) are substantially higher than those of mebendazole. Impaired hepatic function, impaired metabolism, or impaired biliary elimination may lead to higher plasma levels of mebendazole. <br />Mebendazole, the conjugated forms of mebendazole, and its metabolites likely undergo some degree of enterohepatic recirculation and are excreted in the urine and bile. The apparent elimination half-life after an oral dose ranges from 3 to 6 hours in most patients.<br /><em>Ovex&#174; Summary of Product Characteristics, McNeil Products Ltd. Updated April 2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Medroxyprogesterone (IM depot injection)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Medroxyprogesterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Medroxyprogesterone (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction as medroxyprogesterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mefenamic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and glucuronidated by UGT2B7 and UGT1A9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mefloquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefloquine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Megestrol acetate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as megestrol acetate is mainly eliminated in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Meglumine antimoniate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Meglumine antimoniate is predominantly eliminated unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Clinical studies comparing the pharmacokinetics of meglumine antimoniate in adults and children found direct renal clearance to be the predominant route for the elimination of antimony. In the adult group, total weight-adjusted clearance was 0.086&#8211;0.144 L/h/kg (1.43&#8211;2.4mL/min/kg), which is in the same range as the normal adult glomerular filtration rate (GFR). Glomerular filtration was considered to be the predominant mechanism of elimination.<br /><em>Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG. J Infect Dis. 2007 Feb 15;195(4):602-8</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Melarsoprol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of melarsoprol, there is little potential  for interaction, although due to the lack of available data, vigilance is required if administering melarsoprol with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Melarsoprol is a prodrug and is rapidly metabolised to the active form, melarsen oxide. Melarsoprol itself has a plasma half-life of 30 minutes and is excreted in the faeces and urine.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last reviewed 2011-03-03</em></p>
<p>The pharmacokinetics of melarsoprol have not been fully evaluated. Using biological assay and atomic absorption spectrometry, the terminal half-life of melarsoprol was originally calculated to be 35 hours and low trypanocidal activity was detected in the CSF. When the terminal half-life was calculated by high-performance liquid chromatography (HPLC), melarsoprol was found to be eliminated from the plasma within 1 hour. Based on these findings it is thought that melarsoprol is rapidly eliminated from the plasma and transformed into metabolites with trypanocidal activity. Melarsen oxide has been identified by HPLC as a metabolite; the peak plasma concentration was reached 15 minutes after a dose and the half-life of free melarsen oxide was 3.9 hours.<br /><em>Bronner U, et al. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized. Trop Med Int Health 1998; 3: 913&#8211;7.</em></p>
<p>The half-life of melarsoprol determined by HPLC was &lt;1 hour compared with 35 hours determined by bioassay and atomic absorption spectroscopy, indicating the existence of active metabolites. One metabolite, melarsen oxide, was identified by ultraviolet HPLC after incubation of melarsoprol with microsomes. Melarsen oxide could also be detected at the same concentration range in the control run without NaDPH. This indicates that melarsen oxide might not be formed only in a microsomal reaction but also by hydrolysis. The maximum plasma concentration of melarsen oxide was reached 15 minutes after administration; the clearance was 21.5 mL/min/kg and the half-life of free melarsen oxide was 3.9 hours. Either melarsen oxide or a yet-undiscovered active metabolite is irreversibly bound to proteins, as shown by ultrafiltration, precipitation experiments, and atomic absorption spectroscopy. <br /><em>Investigations of the metabolites of the trypanocidal drug melarsoprol. Keiser J, Ericsson O, Burri C. Clin Pharmacol Ther. 2000 May;67(5):478-88.</em></p>
<p>Patients with advanced leukemia (n=8) received escalating intravenous doses of melarsoprol daily for 3 days, repeated weekly for 3 weeks. Doses were 1 mg/kg on day 1, 2 mg/ kg on day 2, and 3.6 mg/kg on day 3 and on all days thereafter, up to a maximum daily dose of 200 mg. Peak plasma concentrations of the parent drug were obtained immediately after injection, which ranged from 1.2 &#181;g/ml on day 1 to 2.4 &#181;g/ml on day 3. Plasma areas under the concentration-times-time curves (AUCs) were proportional to the administered dose, ranging from 0.48 &#181;g.h/ml on day 1 to 1.48 &#181;g.h/ml on day 3. Peak plasma levels were dose-proportional and decayed with a t1/2 of 15 min. Levels of the parent compound were undetectable in plasma at 24 h. There was no detectable level of parent drug in urine at any time. Blood and urine samples were also analyzed for elemental arsenic content. The mean plasma AUC of arsenic on day 1 was 6038 &#181;g.h/ml (range 4497&#177; 9095 &#181;g.h/ml), T1/2a was 38 min and T1/2b was 19.5 h. There was a gradual increase in trough plasma levels of elemental arsenic over the 3-week treatment course.<br /><em>Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Soignet SL, Tong WP, Hirschfeld S, Warrell RP Jr. Cancer Chemother Pharmacol. 1999;44(5):417-21</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Menthol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. There is no evidence to suggest that menthol impacts UGTs.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mephedrone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction as mephedrone is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mercaptopurine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolic/toxicity profiles of both drugs, there is little potential for interaction. Mercaptopurine is predominantly metabolised by xanthine oxidase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The main route of elimination for 6-mercaptopurine is by metabolic alteration. The kidneys eliminate approximately 7% of 6-mercaptopurine unaltered within 12 hours of the drug being administered. Xanthine oxidase is the main catabolic enzyme of 6-mercaptopurine and it converts the drug into the inactive metabolite, 6-thiouric acid. This is excreted in the urine.<br /><em>Puri-Nethol&#174; (Mercaptopurine) 50 mg Tablets UK Summary of Product Characteristics, Aspen, updated May 2012</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Meropenem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3/OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mesalazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mesna</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolic/toxicity profiles of both drugs, there is little potential for interaction. Mesna is rapidly oxidised to its only metabolite, mesna disulphide via the physiological cysteine system. Approximately 32% and 33% of an administered dose is eliminated in the urine in 24 hours as mesna and mesna disulphide respectively.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Analagous to the physiological cysteine system, following intravenous administration, mesna is rapidly oxidised to its only metabolite, mesna disulphide. Mesna disulphide remains in the intravascular compartment and is rapidly eliminated by the kidneys. In the kidney, mesna disulphide is reduced to the free thiol compound, mesna, which acts to detoxify ifosfamide metabolites. Approximately 32% and 33% of the administered dose was eliminated in the urine in 24 hours as mesna and mesna disulphide respectively.<br /><em>Mesna Tablets/Injection US Prescribing Information, Baxter Healthcare Corporation, updated February 2009</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Metformin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly eliminated unchanged in the urine via the renal transporter OCT2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Methadone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No clinically significant change in abacavir pharmacokinetics. Methadone clearance increased by 22%. Patients should be monitored for methadone withdrawal symptoms; dose increase unlikely, but may be required in a small number of patients. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In a pharmacokinetic study, coadministration of 600 mg abacavir twice daily with methadone showed a 35% reduction in abacavir Cmax and a one hour delay in tmax but the AUC was unchanged. The changes in abacavir pharmacokinetics are not considered clinically relevant. In this study abacavir increased the mean methadone systemic clearance by 22%. The induction of drug metabolising enzymes cannot therefore be excluded. Patients being treated with methadone and abacavir should be monitored for evidence of withdrawal symptoms indicating under dosing, as occasionally methadone re-titration may be required. <br /><em>Ziagen Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2011.</em></p>
<p>The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily), with 600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients. The addition of methadone had no clinically significant effect on the pharmacokinetic properties of abacavir. <br /><em>Ziagen Prescribing Information, ViiV Healthcare, May 2012.</em></p>
<p>Methadone concentrations were determined in 5 patients receiving methadone maintenance therapy (12.5-112.5 mg per day) before and after the introduction of amprenavir (1200 mg bd) plus abacavir (600 mg twice daily). Coadministration resulted in a 35% (28-87%) decrease in methadone concentrations. Two patients reported a withdrawal reaction to opioids. <br /><em>Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Bart PA, et al. Ther Drug Monit, 2001, 23: 553-555.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Methamphetamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methamphetamine is mainly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Methotrexate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance there is little potential for an interaction. Methotrexate is predominantly eliminated unchanged via the kidneys, with minimal metabolism. Note, some methotrexate product labels contraindicate its use or advise caution in immunodeficiency and some contraindicate its use in HIV infection.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Methotrexate concentrations were determined in 43 HIV+ patients treated with ARVs and chemotherapy containing high dose methotrexate (3g/m2). Methotrexate elimination half-life was not affected by use of NNRTIs, integrase inhibitors or NRTIs (tenofovir /emtricitabine or abacavir/lamivudine).<br><em>The pharmacokinetics of highdose methotrexate in people living with HIV on antiretroviral therapy. Dalla Pria A, Bendle M, Ramaswami R, et al. Cancer Chemother Pharmacol, 2016, 77:653-657.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Methyldopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied.  Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction.  Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. it is unlikely to affect the disposition of antiretrovirals, or to be altered by co-administration with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. Delayed excretion and accumulation of this metabolite occur in patients with renal insufficiency and may cause an increased hypotensive effect during methyldopa therapy. Unabsorbed methyldopa is excreted in the feces unchanged. Methyldopa is removed by hemodialysis and peritoneal dialysis.<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, 01/2009</em></p>
<p>A study examined the pharmacokinetics and metabolism of methyldopa after single 250mg oral and intravenous doses to 16 healthy human volunteers with a 48-hour washout period between oral and intravenous treatments. Methyldopa was assayed in blood and urine, and its metabolites (methyldopa sulfate, alpha-methyldopamine, and alpha-methyldopamine sulfate) were assayed in urine. The measurable metabolites in urine after oral and intravenous administration accounted for 27% and 17% of the dose, respectively. Methyldopa sulfate was the most abundant metabolite recorded; its quantity was higher after oral than after intravenous administration, 20.1 +/- 5.7% versus 6.7 +/- 5.3% of the dose (P &lt; .05), suggesting significant presystemic gut metabolism. First-pass gut metabolism for methyldopa was estimated to be 17.6 +/- 6.9% of the dose given.<br /><em>Skerjanec A, Campbell NR, Robertson S, Tam YK. Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects. J Clin Pharmacol. 1995 Mar;35(3):275-80.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Methylphenidate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Methylphenidate is not metabolized by cytochrome P450s to a clinically relevant extent and does not inhibit cytochrome P450s.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Methylprednisolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Methylprednisolone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Metoclopramide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolized by CYP450 system (mainly CYP2D6).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Metolazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as metolazone is largely excreted unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Metoprolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Metronidazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase abacavir concentrations due to inhibition of alcohol dehydrogenase by metronidazole.  No a priori dosage adjustment is required as abacavir has a large therapeutic index.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mexiletine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mianserin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Miconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Midazolam (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Midazolam (parenteral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mifepristone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. CYP3A4 is thought to be the main enzyme involved in mifepristone metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>N-Demethylation and terminal hydroxylation of the 17-propynyl chain are primary metabolic pathways of hepatic oxidative metabolism. Mifepristone is mainly excreted in faeces. After administration of a 600 mg labelled dose, 10% of the total radioactivity is eliminated in the urine and 90% in the faeces. No interaction studies have been performed. CYP3A4 is thought to be the main enzyme involved in metabolism&nbsp; <br /><em>Mifegyne&#174; (Mifepristone) 200mg Tablets UK Summary of Product Characteristics, Nordic Pharma Limited, updated July 2011<br />Mifeprex&#174; (Mifepristone) Tablets 200mg US Prescribing Information, Danco Laboratories LLC, updated April 2009</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Milk thistle</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drug-drug interaction studies suggest that milk thistle has limited clinical impact on substrates of CYP3A, P-gp, UGT and OATP.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Milnacipran</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Miltefosine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of miltefosine, there is little potential for interaction. In vitro studies have shown that interactions between miltefosine and drugs which are metabolised by cytochrome P450, glucuronidated or otherwise conjugated are unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>In vitro studies have shown that interactions between miltefosine and drugs which are metabolised by cytochrome P450, glucuronidated or otherwise conjugated are unlikely, however the possibility of interactions with commonly used drugs can not be totally excluded. No oxidative metabolism of miltefosine was observed in in vitro studies with 15 CYP450 Isozymes. No CYP3A induction was observed in animal studies. A slow metabolic degradation in human hepatocytes was demonstrated, in which a phospholipase D-like cleavage of miltefosine causes the release of choline. Preclinical and clinical studies suggest that only a very small proportion of the administered dose is excreted in the unchanged form. The most likely excreted products are choline and choline-containing products.<br /><em>Impavido&#174; (Miltefosine) Capsules German Product Information, Paladin Labs Ltd, updated September 2009</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mirabegron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mirtazapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Misoprostol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Misoprostol is predominantly metabolised via fatty acid oxidising systems.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Misoprostol is predominantly metabolised via fatty acid oxidising systems and has shown no adverse effect on the hepatic microsomal mixed function oxidase (P450) enzyme system. In specific studies no clinically significant pharmacokinetic interaction has been demonstrated with antipyrine or diazepam. A modest increase in propranolol concentrations (mean approximately 20% in AUC, 30% in Cmax) has been observed with multiple dosing of misoprostol. In extensive clinical studies no drug interactions have been attributed to Misoprostol. <br /><em>Cytotec&#174; (Misoprostol) Tablets UK Summary of Product Characteristics, Pharmacia Limited updated November 2010</em></p>
<p>Misoprostol is extensively absorbed, and undergoes rapid deesterification to its free acid, which is responsible for its clinical activity and, unlike the parent compound, is detectable in plasma. The alpha side chain undergoes beta oxidation and the beta side chain undergoes omega oxidation followed by reduction of the ketone to give prostaglandin F analogs. Maximum plasma concentrations of misoprostol acid are diminished when the dose is taken with food and total availability of misoprostol acid is reduced by use of concomitant antacid. Clinical trials were conducted with concomitant antacid, however, so this effect does not appear to be clinically important. Drug interaction studies between misoprostol and several nonsteroidal anti-inflammatory drugs showed no effect on the kinetics of ibuprofen or diclofenac, and a 20% decrease in aspirin AUC, not thought to be clinically significant. Pharmacokinetic studies also showed a lack of drug interaction with antipyrine and propranolol when these drugs were given with misoprostol. Misoprostol given for 1 week had no effect on the steady state pharmacokinetics of diazepam when the two drugs were administered 2 hours apart.<br /><em>Cytotec&#174; (Misoprostol) tablets US Prescribing Information, Pfizer Inc, Revised September 2009</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mitoxantrone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Modafinil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Modafinil is largely metabolized by hydrolysis (esterase mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mometasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Montelukast</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Morphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically relevant drug interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Abacavir does not affect this metabolic pathway. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Moxifloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Mycophenolate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Mycophenolate mofetil is a prodrug of mycophenolic acid (MPA). MPA undergoes glucuronidation; coadministration of those NRTIs which are also glucuronidated (i.e. abacavir or zidovudine) could alter mycophenolate levels. Concentration monitoring of mycophenolate is recommended. Mycophenolate had no significant effect on abacavir plasma concentrations or intracellular phosphorylated metabolites. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The effect of mycophenolate (500 mg twice daily) on the pharmacokinetics of abacavir was studied in HIV-infected subjects receiving abacavir (300 mg twice daily), didanosine (400 mg once daily), lamivudine (150 mg twice daily), indinavir, ritonavir and nevirapine alone (n=10) and in combination with mycophenolate (n=9). The AUC and clearance of abacavir were not statistically significantly different in the two groups. Median Cmax values were 1.86 vs. 1.98 mg/L (alone vs. combination) and AUC values were 3.25 vs. 3.67 mg.h/L (alone vs. combination). There were no significant differences in intracellular concentrations of dGTP between the two groups.<br /><em>Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Sankatsing SUC, et al. Clin Pharmacokinet, 2004, 43; 823-832.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Naftidrofuryl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naftidrofuryl is metabolized to 3 major metabolites primarily by plasma pseudo-choline esterases</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Naltrexone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have shown that neither naltrexone, nor its main metabolite (6-beta-naltrexol), is metabolized by CYP450 enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nandrolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance there is little potential for pharmacokinetic interaction. Nandrolone is metabolized in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Naproxen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nateglinide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is metabolized mainly by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nebivolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nebivolol metabolism involves CYP2D6</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nefazodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nefazodone is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nelfinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Clinically significant interactions have not been observed between nelfinavir and nucleoside analogues. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Clinically significant interactions have not been observed between nelfinavir and nucleoside analogues. <br /><em>Viracept Summary of Product Characteristics, Roche Products Ltd, September 2011. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Neostigmine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Neostigmine is thought to undergo a degree of hepatic metabolism, although the mechanisms are unknown. However, as metabolism also occurs via hydrolysis by cholinesterase and up to 50% of a dose is excreted unchanged via the kidneys, there is little potential for clinically significant interaction with antiretrovirals via modification of hepatic metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver. Protein binding to human serum albumin ranges from 15 to 25 percent. Following intramuscular administration, Neostigmine is rapidly absorbed and eliminated. In a study of five patients with myasthenia gravis, peak plasma levels were observed at 30 minutes, and the half-life ranged from 51 to 90 minutes. Approximately 80 percent of the drug was eliminated in urine within 24 hours; approximately 50% as the unchanged drug and 30 percent as metabolites.<br /><em>Neostigmine Methylsulfate Injection USP UA Prescribing Information, American Reagent Inc, updated January 2009</em></p>
<p>Neostigmine kinetics and metabolism were studied after intracellular administration to 8 patients with myasthenia gravis. The plasma neostigmine level declined monoexponentially from 21 +/- 2 to 9 +/- 1 ng/ml between 30 and 120 min. Approximately 80% of the drug was eliminated in urine within 24 hr either as unchanged neostigmine or its metabolites. Approximately 50% of the dose was eliminated as the unchanged drug, 15% as 3-hydroxyphenyltrimethylammonium, and 15% as other unidentified metabolites. The neostigmine t1/2, based on the urinary excretion of the unchanged drug, ranged from 90.2 to 118.7 min. It was concluded that neostigmine was eliminated by renal and extrarenal mechanisms.<br /><em>Somani SM, Chan K, Dehghan A, Calvey TN. Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis. Clin Pharmacol Ther. 1980 Jul;28(1):64-8.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nevirapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nicardipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nicardipine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Niclosamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. After oral administration, absorption of niclosamide is considered minimal.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>After oral administration, 2-25% of the administered dose is detected in urine. Absorption is considered minimal<br /><em>Yomesan&#174; Summary of Product Characteristics (Germany), Bayer Vital, Updated January 2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nicorandil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of nicorandil takes place mainly via denitration with the denitrated product then merging into the nicotinamide pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nicotinamide (Niacinamide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Nicotinic acid and its metabolites do not inhibit CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4-mediated reactions or UGT1A1-mediated 3-glucuronidation in vitro.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Nicotinic acid and nicotinamide are readily absorbed from the gastrointestinal tract after oral doses and widely distributed in the body tissues. The main route of metabolism is their conversion to N-methylnicotinamide and the 2-pyridone and 4-pyridone derivatives; nicotinuric acid is also formed. Small amounts of nicotinic acid and nicotinamide are excreted unchanged in urine after therapeutic doses; however the amount excreted unchanged is increased with larger doses.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via medicines Complete), last modified 2006-01-26</em> </p>
<p>In in vitro studies, nicotinic acid and its metabolites did not inhibit CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4-mediated reactions or UGT1A1-mediated 3-glucuronidation of estradiol.<br /><em>Tredaptive&#174; (Nicotinic acid/laropiprant) modified release tablets, UK Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated May 2012</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nifedipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nifurtimox</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of nifurtimox, there is little potential  for interaction, although due to the lack of data, vigilance is required if administering nifurtimox with antiretrovirals. Nifurtimox appears to be biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Oral nifurtimox is well absorbed and peak serum concentrations occur after 4 hours. It is rapidly and extensively metabolised and relatively low concentrations of nifurtimox appear in the plasma and tissues. It is presumed to cross the blood-brain barrier. Less than 1% of an oral dose is excreted unchanged in the urine. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last reviewed 2011-03-03</em></p>
<p>Nifurtimox (Nfx) has serious toxic effects including mutagenic, reproductive and carcinogenic actions. Its toxicity has been linked to NADPH dependent nitroreductive metabolic biotransformation with production of oxygen reactive species. Rat liver nuclei exhibit Nfx-nitroreductase activity (Nfx-ase). This activity is null under oxygen and partially inhibited under CO. Results suggest that Nfx is biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase. Formation of reactive metabolites nearby DNA and nuclear proteins might be related to long term deleterious effects of this drug.<br /><em>Rat liver nuclear nifurtimox nitroreductase activity. de Toranzo EG, Herrera DM, Castro JA. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):249-54.</em></p>
<p>Liver microsomal (mic); nuclei (N) and mitochondria (mit) anaerobically nitroreduce Nifurtimox (Nfx) in the presence of NADPH generating system. Simultaneous formation of small amounts of nitrite was observed in microsomes and nuclei but not in mitochondria. The microsomal nitroreductase activity was enhanced by the presence of flavine-adenine-dinucleotide disodium salt (FAD), was not inhibited by CO and was significantly inhibited by diphenyleneiodonium (DPI). In the microsomal NADPH-dependent fraction nitrite formation was null in the presence of FAD, DPI and under air and was partially inhibited by pure CO. Pure human cytochrome P450 reductase in the presence of NADPH significantly nitroreduced Nfx and produced small amounts of nitrite. The nitroreductive process was significantly enhanced by FAD but the nitrite formation became null. FAD itself was able to chemically nitroreduce Nfx without production of nitrite. NADPH generating system enhanced the FAD nitroreductive effect and led to small production of nitrite. Formation of reactive metabolites and nitric oxide during Nfx metabolism might contribute to its toxicity.<br /><em>Nifurtimox biotransformation to reactive metabolites or nitrite in liver subcellular fractions and model systems. Montalto de Mecca M, Diaz EG, Castro JA. Toxicol Lett. 2002 Nov 15;136(1):1-8</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nilotinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Nilotinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nimesulide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nisoldipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nisoldipine is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nitrendipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nitrofurantoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. 30-40% of a nitrofurantoin dose is eliminated unchanged via the kidneys, with a small proportion metabolized to aminofurantoin.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Nitrofurantoin is metabolised in the liver and most body tissues while about 30 to 40% of a dose is excreted rapidly in the urine as unchanged nitrofurantoin. Some tubular reabsorption may occur in acid urine. Average doses give a concentration of 50 to 200 micrograms/mL in the urine in patients with normal renal function.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press, (via medicines Complete), last reviewed 20/8/2010</em> </p>
<p>Nitrofurantoin 50mg was administered in a three-way random crossover design to six healthy men. After a 45-mM intravenous infusion the plasma concentration data could be described by a two-compartment open-body model with a terminal halflife of 58.1 &#177; 15 min. Although absorption appeared to be complete, the absorption rate profile was complex and erratic. Two subjects failed to achieve the minimum effective urine concentration of 32 microgramslml. After the intravenous infusion 47 % of the dose was excreted unchanged in the urine and 1.2 % was recovered as the reduced metabolite aminofurantoin. After oral administration, 34% was excreted unchanged in urine.<br /><em>Nitrofurantoin disposition. Hoener B, Patterson SE. Clin Pharmacol Ther. 1981 Jun;29(6):808-16.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nitrous oxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Most inhaled nitrous oxide is rapidly eliminated unchanged through the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Nitrous oxide is rapidly absorbed on inhalation. The blood/gas partition coefficient is low and most of the inhaled nitrous oxide is rapidly eliminated unchanged through the lungs though small amounts diffuse through the skin.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Norelgestromin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as norelgestromin is metabolized to norgestrel (possibly by CYP3A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Norethisterone (Norethindrone)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction as norethisterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Norgestimate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as norgestimate is rapidly deacetylated to the active metabolite which is further metabolized via CYP450.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Norgestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nortriptyline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nortriptyline is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Nystatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Nystatin is formulated in oral and topical dosage forms and is not systemically absorbed from any of these preparations. Interaction with other medicinal products and other forms of interaction: None known<br /><em>Nystan oral suspension&#174; Summary of product Characteristics, E. R. Squibb &amp; Sons Limited, updated February 2010</em></p>
<p>Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.<br /><em>Nystatin oral suspension USP US Prescribing Information, Taro Pharmaceuticals U.S.A., Inc., updated March 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely as ofloxacin is primarily eliminated by the kidney.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Olanzapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Olmesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan which is eliminated in the faeces and urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ombitasvir/Paritaprevir/r</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration with ombitasvir/paritaprevir/ritonavir has not been studied. Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and abacavir/lamivudine (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects and had no clinically significant effect on the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, abacavir or lamivudine. No dose adjustment is required for ombitasvir/paritaprevir/ritonavir or abacavir during coadministration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and abacavir/lamivudine (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects. During coadministration abacavir exposures were up to 13% lower; lamuvidine Cmax and AUC were up to 13% lower and Ctrough was 29% higher. Exposure of ombitasvir and dasabuvir were up to 18% lower, and paritaprevir and ritonavir Ctrough both decreased by 34%. No dose adjustment is recommended for ombitasvir/paritaprevir/ritonavir + dasabuvir or abacavir/lamuvudine during coadministration.<br /><em>Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine.<br />Khatn A, Trinh R, Zhao W, et al. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, May 2015, Abstract 57.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ombitasvir/Paritaprevir/r + Dasabuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and abacavir/lamivudine (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects and had no clinically significant effect on the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, abacavir or lamivudine. No dose adjustment is required for ombitasvir/paritaprevir/ritonavir + dasabuvir or abacavir during coadministration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and  abacavir/lamivudine (600/300 mg once daily) was studied in 12  HIV/HCV-negative subjects. During coadministration abacavir exposures  were up to 13% lower; lamuvidine Cmax and AUC were up to 13% lower and  Ctrough was 29% higher. Exposure of ombitasvir and dasabuvir were up to  18% lower, and paritaprevir and ritonavir Ctrough both decreased by 34%.  No dose adjustment is recommended for ombitasvir/paritaprevir/ritonavir  + dasabuvir or abacavir/lamuvudine during coadministration.<br /><em>Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine.<br />Khatn  A, Trinh R, Zhao W, et al. 16th International Workshop on Clinical  Pharmacology of HIV and Hepatitis Therapy, Washington DC, May 2015,  Abstract 57.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Omeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Omeprazole is mainly metabolized by CYP2C19 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ondansetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolized mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Orlistat</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as orlistat is mainly eliminated unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oseltamivir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases which is then excreted in the urine by glomerular filtration and tubular secretion by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oxaliplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oxamniquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Oxamniquine is thought to be predominantly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Oxamniquine is extensively metabolised to inactive metabolites, mainly the 6-carboxy derivative, which are excreted in the urine. About 70% of a dose of oxamniquine is excreted as the 6-carboxy metabolite within 12 hours of a dose; traces of the 2-carboxy metabolite have also been detected in the urine. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 12-March-2011</em></p>
<p>In vitro studies using human liver microsomes suggest that oxamniquine competitively inhibits CYP2D6 activity. The authors suggest that due to high affinity for the CYP2D6 receptor, oxamniquine may also be a substrate for this metabolic enzyme.<br /><em>Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Masimirembwa CM, Hasler JA, Johansson I. Eur J Clin Pharmacol. 1995;48(1):35-8.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oxandrolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oxazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated by UGTs 2B15, 1A9 and 2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oxcarbazepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Oxcarbazepine is rapidly reduced by cytosolic arylketone reductases to its active metabolite, 10-hydroxycarbazepine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oxprenolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as oxprenolol is largely metabolised by glucuronidation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oxybutynin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxybutynin is metabolized by CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oxycodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Oxytocin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. However, As few data are available, care should be taken when administering oxytocin with antiretrovirals. Elimination of oxytocin occurs  via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The plasma half-life of oxytocin is of the order of five minutes, hence the need for continuous iv infusion. Elimination is via the liver, kidney, functional mammary gland and oxytocinase.<br /><em>Syntocinon&#174; (Oxytocin) Ampoules 10 IU/ml UK Summary of Product Characteristics, Alliance Pharmaceuticals, updated March 2007</em></p>
<p>Oxytocin has a plasma half-life of about 1 to 6 minutes which is decreased in late pregnancy and during lactation. Following intravenous administration of oxytocin, uterine response occurs almost immediately and subsides within 1 hour. Following intramuscular injection of the drug, uterine response occurs within 3 to 5 minutes and persists for 2 to 3 hours. Its rapid removal from plasma is accomplished largely by the kidney and the liver. Only small amounts are excreted in urine unchanged.<br /><em>Pitocin&#174; (Oxytocin Injection, USP, synthetic) US Prescribing Information, JHP Pharmaceuticals LLC, updated December 2007</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Paclitaxel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Paliperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pantoprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolized by CYP2C19 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Para-aminosalicylic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Para-aminosalicylic acid is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Aminosalicylic acid and its metabolites are excreted in urine by glomerular filtration and tubular secretion. Following a single 4-g dose of aminosalicylic acid in adults with normal renal function, approximately 77% of the dose is excreted in urine within 24 hours; 56% is excreted as the acetylated metabolite. Aminosalicylic acid and its acetyl metabolite accumulate in patients with severe renal disease. Continued acetylation of the parent drug leads exclusively to accumulation of the inactive acetylated form; deacetylation, if it occurs, is minor. <br /><em>Paser&#174; granules (aminosalicylic acid granules) US prescribing information, Jacobus Pharmaceutical Co.&nbsp; Last updated August 1996</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Paracetamol (Acetaminophen)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (UGT1A9 (major), UGT1A6, UGT1A1, UGT2B15), sulfation and, to a lesser extent, by oxidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Paromomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Paromomycin is not metabolized, it is eliminated unchanged by renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The bioavailablity of paromomycin in patients following IM administration is very high, approaching 100%, and is negligible following oral administration; thus, IM administration is required to treat systemic infections like VL. The average half-life of paromomycin in humans is 2&#8211;3 hours. Paromomycin is not metabolized &#8212;it is removed from the plasma by glomerular filtration and excreted unchanged in the urine; thus, accumulation can occur in patients with diminished renal function.<br /><em>Paromomycin Solution for Intramuscular Injection (375 mg/mL) Gland Pharma Ltd, in association with One World Health.From: Application for inclusion of paromomycin in the WHO Model List of Essential Medicines 12/10/2006, World Health Organisation archives, available at: </em><a href="http://archives.who.int/eml/expcom/expcom15/applications/newmed/paromomycin/paromomycin.pdf"><em>http://archives.who.int/eml/expcom/expcom15/applications/newmed/paromomycin/paromomycin.pdf</em></a><em> accessed 3/4/2012</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Paroxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolized by CYP2D6 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pazopanib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Pazopanib is metabolized by CYP3A4 and to a lesser extent 1A2 and 2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Peginterferon alfa-2a</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Hepatic decompensation (some fatal) has occurred in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia. Some data suggest that HIV/HCV co-infected patients receiving abacavir-containing ART may be at risk of a lower response rate to pegylated interferon/ribavirin therapy although this has not been confirmed in other studies.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Patients receiving PEGASYS (peginterferon alfa-2a)/COPEGUS (ribavirin) and NRTIs should be closely monitored for treatment associated toxicities. Physicians should refer to prescribing information for the respective NRTIs for guidance regarding toxicity management. In addition, dose reduction or discontinuation of PEGASYS (peginterferon alfa-2a), COPEGUS (ribavirin) or both should also be considered if worsening toxicities are observed.<br /><em>Copegus US Prescribing Information, Genetech USA Inc, June 2010.</em></p>
<p>Hepatic decompensation (some fatal) has occurred in cirrhotic HIV/HCV co-infected patients receiving combination antiretroviral therapy for HIV and interferon alpha and ribavirin. Adding treatment with alpha interferons alone or in combination with ribavirin may increase the risk in this patient subset. Patients receiving interferon with ribavirin and nucleoside reverse transcriptase inhibitors (NRTIs) should be closely monitored for treatment- associated toxicities, especially hepatic decompensation and anemia. Discontinuation of NRTIs should be considered as medically appropriate. Dose reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh &gt;6).<br /><em>Rebetol US Prescribing Information, Schering Corporation, November 2009.</em></p>
<p>Cirrhotic&nbsp; chronic HCV patients coinfected with HIV receiving highly active antiretroviral therapy (HAART) and interferon alfa-2a with or without ribavirin appear to be at increased risk for the development of hepatic decompensation compared to patients not receiving HAART. In a study of 129 HCV/HIV cirrhotic patients receiving HAART, 14 (11%) of these patients across all treatment arms developed hepatic decompensation resulting in 6 deaths. All 14 patients were on NRTIs, including stavudine, didanosine, abacavir, zidovudine, and lamivudine. These small numbers of patients do not permit discrimination between specific NRTIs for the associated risk. During treatment, patients&#8217; clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score &#8805;6) is observed. Patients receiving PEGASYS/COPEGUS and NRTIs should be closely monitored for treatment associated toxicities. Physicians should refer to prescribing information for the respective NRTIs for guidance regarding toxicity management. Dose reduction or discontinuation of PEGASYS, COPEGUS or both should also be considered if worsening toxicities are observed.<br /><em>Pegasys US Prescribing Information, Genentech Inc, June 2010.</em></p>
<p>Hepatic decompensation (some fatal) has occurred in cirrhotic HIV/HCV coinfected patients receiving combination antiretroviral therapy for HIV and interferon alpha and ribavirin. Adding treatment with alpha interferons alone or in combination with ribavirin may increase the risk in this patient subset. Patients receiving interferon with ribavirin and nucleoside reverse transcriptase inhibitors (NRTIs) should be closelymonitored for treatment-associated toxicities, especially hepatic decompensation and anemia. Discontinuation of NRTIs should be considered as medically appropriate.Dose reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh &gt;6).<br /><em>PegIntron US Prescribing Information, Schering Corporation, January 2010</em>.</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Penicillamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction. Although metabolism of penicillamine is not fully elucidated, multiple mechanisms and sites of metabolism are thought to be involved. There is therefore low potential for clinically significant interactions with abacavir via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Penicillamine is absorbed rapidly but incompletely (40-70%) from the gastrointestinal tract, with wide inter-individual variations. Food, antacids, and iron reduce absorption of the drug. The peak plasma concentration of penicillamine occurs 1-3 hours after ingestion; it is approximately 1-2mg/L after an oral dose of 250 mg. The drug appears in the plasma as free penicillamine, penicillamine disulfide, and cysteine-penicillamine disulfide. When prolonged treatment is stopped, there is a slow elimination phase lasting 4-6 days. More than 80% of plasma penicillamine is bound to proteins, especially albumin and ceruloplasmin. The drug also binds to erythrocytes and macrophages. A small fraction of the dose is metabolized in the liver to S-methyl-D-penicillamine. Excretion is mainly renal, mainly as disulfides.<br /><em>Cuprimine&#174; (Penicillamine) capsules, US Prescribing Information, Aton Pharma, updated October 2008</em></p>
<p>Very little information is available on the metabolism of the penicillamine that is not excreted as part of a metal or cysteine complex. The drug is believed to be metabolized in the liver and excreted in urine and feces, principally as inactive disulfides: penicillamine disulfide, penicillamine-cysteine disulfide, and small amounts of S-methyl-d-penicillamine. The manufacturers report that penicillamine is rarely excreted unchanged in urine. In one study, about 50% of a dose of penicillamine was excreted in urine, about 20% in feces, and about 30% was unaccounted for after 24 hours.<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, updated April 2009</em></p>
<p>The transformation of D-penicillamine (D-pen) was studied in orally- and intravenously-dosed rats and in human plasma in vitro. In each case, low molecular weight (LMW) metabolites (previously identified as disulphides) and a mixed disulphide between D-pen and albumin (D-pen-protein) formed. The rates of D-pen elimination, other than through protein conjugation, were comparable in the rat groups to the rate of oxidation to LMW metabolites in vitro. The rates of transformation to D-pen-protein were also comparable in the in vitro preparations and in orally-treated rats. These qualitative and quantitative similarities suggest blood plasma may be an important site of transformation in vivo. Extracellular oxidation of D-pen may be linked to its antirheumatic action, either through reduction of oxygen species or through formation of D-pen-protein disulphides at surfaces of mononuclear leukocytes.<br /><em>Joyce DA, Murphy BR. D-penicillamine metabolism: the role of transformation in blood plasma. Agents Actions. 1990 Nov;31(3-4):353-7</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Penicillins</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pentamidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The exact metabolic pathway of pentamidine has not been clearly established. Data from animal studies suggest the involvement of CYPs 1A1, 2D6 and 2C19 in the oxidative metabolism of pentamidine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pentoxifylline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pentoxifylline has not been well described but some studies indicate oxidation by CYP1A2, reduction by carbonyl reductase, and oxidation by carboxylase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Perazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9, and oxidated by FMO3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pericyazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pericyazine has not been well characterized but is likely to involve CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Perindopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolized to other inactive metabolites. Elimination occurs predominantly via the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Perphenazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as perphenazine is metabolized by CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pethidine (Meperidine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Phencyclidine (PCP)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Phenelzine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolized by oxidation via monoamine oxidase and to a lesser extent by acetylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Phenobarbital (Phenobarbitone)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Potential decrease in abacavir plasma concentrations. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Potent enzymatic inducers such as rifampicin, phenobarbital and phenytoin may via their action on UDP-glucuronyltransferases slightly decrease the plasma concentrations of abacavir. <br /><em>Ziagen Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Phenprocoumon</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is metabolized by CYP2C9 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Phenytoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Potential decrease in abacavir plasma concentrations. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Potent enzymatic inducers such as rifampicin, phenobarbital and phenytoin may via their action on UDP-glucuronyltransferases slightly decrease the plasma concentrations of abacavir. <br /><em>Ziagen Summary of Product Characteristics,&nbsp;ViiV Healthcare UK Ltd, October 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Phytomenadione (Vitamin K)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Metabolism of phytomenadione is thought to involve glucuronidation, however as glucuronidation is not the sole route of elimination, there is little potential for interaction with abacavir via competition for glucuronidation pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Vitamin K1 is converted to more polar metabolites, such as phytomenadione-2,3-epoxide. The half-life of vitamin K1 in plasma is about 1.5 to 3 hours. Vitamin K1 is excreted in the bile and urine as glucuronide and sulphate conjugates.<br /><em>Konakion MM&#174; (phytomenadione) 2mg/0.2ml paediatric ampoules Product Information, Hoffmann-La Roche Ltd, updated November 2006</em> </div>
<div>&nbsp;</div>
<div>An in vitro study aimed to determine the role of CYP4F2 in the metabolism of vitamin K1 by human liver. In vitro metabolic experiments with accompanying liquid chromatography-tandem mass spectrometry analysis demonstrated that recombinant CYP4F2 (Supersomes) and human liver microsomes supplemented with NADPH converted vitamin K1 to a single product. A screen of all commercially available P450 Supersomes showed that only CYP4F2 was capable of metabolizing vitamin K1 to this product. These data demonstrate that CYP4F2 is a vitamin K(1) oxidase and that carriers of the CYP4F2 V433M allele have a reduced capacity to metabolize vitamin K1, secondary to an rs2108622-dependent decrease in steady-state hepatic concentrations of the enzyme. <br /><em>CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. Mol Pharmacol. 2009 Jun;75(6):1337-46.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pilocarpine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction when pilocarpine is used either orally or as eye drops. Pilocarpine is primarily metabolized by CYP2A6 and serum esterases, there is therefore little potential for interaction with abacavir via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><strong>Systemic use:</strong> Pilocarpine is primarily metabolized by CYP2A6 and has demonstrated a capacity to inhibit CYP2A6 in vitro. Serum esterases are also involved in the biotransformation of pilocarpine to pilocarpic acid. Approximately 35% of dose is eliminated as 3-hydroxypilocarpine in urine and 20% of dose is excreted unchanged in the urine. Mean elimination half-lives for pilocarpine is 0.76 and 1.35 hours after repeated oral doses of 5 and 10 mg of pilocarpine hydrochloride, respectively.<br /><em>Salagen&#174; (Pilocarpine) 5mg Film Coated Tablets UK Summary of Product Characteristics, Novartis Pharmaceuticals UK Ltd, updated November 2011</em></p>
<p><strong>Ocular use:</strong> Systemic reactions rarely occur when treating chronic simple glaucoma at normal doses. However, in the treatment of acute closed-angle glaucoma the possibility of systemic reactions must be considered because of the higher doses given. Pilocarpine has a low ocular bioavailability when topically applied and this has been attributed to extensive pre-corneal drug loss in conjunction with the resistance to normal corneal penetration. Further, pilocarpine appears to bind to the eye pigments from which it is gradually released to the muscles. Inactivation of pilocarpine in the eye is thought to occur by a hydrolysing enzyme. The amount of this enzyme is not changed by the prolonged use of pilocarpine by glaucoma patients, nor is it changed in patients poorly controlled by glaucoma therapy.<br /><em>Minims Pilocarpine Nitrate 2% w/v Eye drops solution UK Summary of Product Characteristics, Bausch &amp; Lomb U.K Limited, updated July 2012</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pimozide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pindolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolized to hydroxymetabolites (possibly by CYP2D6) and partly eliminated unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pioglitazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolized by mainly CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pipotiazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Piroxicam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as piroxicam is primarily metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pitavastatin </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Posaconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as posaconazole is glucuronidated by UGT1A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Potassium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as potassium is eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pramipexole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pramipexole is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Prasugrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pravastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Praziquantel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Praziquantel is predominantly metabolised via CYP3A4, whereas abacavir is metabolised via alcohol dehydrogenase and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Praziquantel is metabolised via various cytochrome P450 isoenzymes, mainly CYP2B1 and CYP3A4, and therefore has the potential to interact with drugs that are inhibitors or inducers of such enzymes. Enzyme-inducing drugs such as carbamazepine, dexamethasone, phenobarbital, and phenytoin may decrease plasma concentrations of praziquantel. Conversely, enzyme inhibitors such as cimetidine, erythromycin, itraconazole, and ketoconazole may increase plasma concentrations of praziquantel. It is excreted in the urine, mainly as metabolites which are thought to be inactive.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Prazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Prazosin undergoes extensive hepatic metabolism primarily by demethylation and conjugation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Prednisolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisolone undergoes hepatic metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Prednisone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pregabalin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as pregabalin is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Primaquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Probenecid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. In vitro data suggest that probenecid is a non-selective inhibitor of UGT and coadministration could increase abacavir concentrations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Procarbazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction.  Procarbazine is metabolized to azoprocarbazine by CYP450 (mainly CYP2B and 1A) and monoamine oxidase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Prochlorperazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Proguanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Promethazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Propafenone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Propofol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propofol is glucuronidated via UGT1A9, UGT1A8 and is oxidized mainly via CYP2B6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Propranolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Propylthiouracil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Propylthiouracil is extensively metabolised, predominantly via glucuronidation. The exact glucuronidation pathways are unknown. There are no data to suggest that propylthiouracil inhibits/induces glucuronidation, therefore there is little potential for clinically significant interaction with abacavir via modulation of glucuronidation pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Propylthiouracil is readily absorbed and is extensively metabolized. Approximately 35% of the drug is excreted in the urine, in intact and conjugated forms, within 24 hours.<br /><em>Propylthiouracil tablets US Prescribing Information, DAVA Pharmaceuticals Inc. updated February 2010</em></p>
<p>Although the exact metabolic fate of propylthiouracil has not been fully established, the drug is extensively metabolized to its glucuronide conjugate and other minor metabolites. The drug and its metabolites are excreted in urine, with about 35% of a dose excreted within 24 hours<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, updated October 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Protamine sulphate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on very limited data concerning the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. The metabolism of protamine has not been fully elucidated, however protamine complexed with heparin is thought to be partially metabolised by fibrinolysin.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Protamine sulphate has a rapid onset of action. Following intravenous administration, neutralisation of heparin occurs within 5 minutes. Although the metabolic fate of the protamine-heparin complex is not known, it appears that the complex is partially degraded, thus freeing heparin. No interactions are known.<br /><em>Protamine Sulphate Injection BP 1% UK Summary of Product Characteristics, Sovereign Medical, updated September 2007<br />Prosulf&#174; (protamine sulphate)10mg/ml Solution for Injection UK Summary of Product Characteristics, Wockhardt UK Ltd updated September 2010</em></p>
<p>Although the metabolic fate of the protamine-heparin complex has not been elucidated, it appears that the protamine in the heparin-protamine complex may be partially metabolized or attacked by fibrinolysin, thus freeing heparin<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, December 2008</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Prucalopride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly eliminated renally, partly by active secretion by renal transporters. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pyrantel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Pyrantel is metabolized by CYP2D6 in vitro, however absorption of an oral dose is minimal, and over 50% of a dose is excreted unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Only a small proportion of a dose of pyrantel embonate is absorbed from the gastrointestinal tract. Up to about 7% is excreted as unchanged drug and metabolites in the urine but over half of the dose is excreted unchanged in the faeces.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em></p>
<p>Pyrantel is predominantly metabolised by CYP2D6 in vitro<br /><em>Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Li XQ, Bj&#246;rkman A, Andersson TB, et al. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.</em> </p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pyrazinamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolized by xanthine oxidase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pyridostigmine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Pyridostigmine is predominantly eliminated unchanged via renal tubular secretion, there is therefore little potential for interaction with abacavir via modulation of or competition for metabolism pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Pyridostigmine bromide is poorly absorbed from the gastrointestinal tract. It undergoes hydrolysis by cholinesterases and is also metabolised in the liver. Pyridostigmine is excreted mainly in the urine as unchanged drug and metabolites. It appears that 75% of the plasma clearance of pyridostigmine depends on renal function. 3-Hydroxy-N-methylpyridinium has been identified as one of the 3 metabolites isolated from the urine of patients taking pyridostigmine.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press(via Medicines Complete), last modified 2011-04-15</em><br />&nbsp;<br />To assess the contribution of tubular secretion to the renal excretion of pyridostigmine, and its modification by other cationic drugs, six volunteers were given single oral doses of 60mg pyridostigmine bromide with and without co-administration of ranitidine or pirenzepine. In patients with myasthenia receiving continuous pyridostigmine therapy, renal clearance values were obtained in the same manner with and without ranitidine (10 patients) or pirenzepine (nine patients) co-medication. Pyridostigmine renal clearance averaged 6.65 ml/min per kg (350% of the creatinine clearance) in all subjects, 74% being due to net tubular secretion. Mean values for pyridostigmine renal clearance and for clearance by secretion were decreased in the presence of pirenzepine, but plasma concentrations were not affected significantly. Ranitidine caused a small non-significant decrease of the pyridostigmine clearance in patients. The renal clearance of creatinine was slightly increased by pyridostigmine in volunteers and slightly decreased by pirenzepine in the total group of subjects.<br /><em>Eiermann B, Sommer N, Winne D, Schumm F, Maier U, Breyer-Pfaff U. Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. Xenobiotica. 1993 Nov;23(11):1263-75.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pyridoxine (Vitamin B6)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid.<br /><em>Vitamin B Compound Strong Tablets, UK Summary of Product Characteristics, Actavis UK Ltd, updated July 2012</em></p>
<p>Pyridoxine, pyridoxal, and pyridoxamine are readily absorbed from the gastrointestinal tract after oral doses and are converted to the active forms pyridoxal phosphate and pyridoxamine phosphate. They are stored mainly in the liver where there is oxidation to 4-pyridoxic acid and other inactive metabolites which are excreted in the urine. As the dose increases, proportionally greater amounts are excreted unchanged in the urine.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last modified 2006-07-17</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Pyrimethamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Quercetin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Quetiapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is primarily metabolised by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Quinapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Quinidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinidine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Quinine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as quinine is extensively metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rabeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rabeprazole is mainly metabolized by CYP2C19 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Raltegravir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration increased abacavir AUC and Cmax by 3% and 6%, respectively; Cmin decreased by 17%. Studies are required to relate the change in plasma abacavir exposure to the active intracellular carbovir triphosphate. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The steady-state plasma pharmacokinetics of abacavir (600 mg once daily) were investigated when co-administered with raltegravir (400 mg twice daily) to 19 HIV+ subjects. When coadministered with raltegravir, the AUC and Cmax of abacavir increased by 3% and 6%, respectively; Cmin decreased by 17%. . It is important to relate the change in plasma abacavir exposure to the active intracellular carbovir triphosphate and a study is in progress. <br /><em>Pharmacokinetics (PK) of plasma abacavir (ABC) in the absence and in the presence of darunavir/ritonavir (DRV/r) or raltegravir (RAL) in HIV-infected subjects. Jackson A, Gedela K, Dickinson L, et al. 12th European AIDS Conference (EACS), Cologne, November 2009, abstract PE4.3/2.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ramipril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolized to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ranitidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranitidine is excreted via the kidney, partially by the cationic system.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ranolazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranolazine is primarily metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rasagiline </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as rasagiline is metabolised predominantly by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Reboxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as reboxetine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Repaglinide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolized by CYP2C8 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Retinol (Vitamin A)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Vitamin A substances are readily absorbed from the gastrointestinal tract but absorption may be reduced in the presence of fat malabsorption, low protein intake, or impaired liver or pancreatic function. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. It is released from the liver bound to a specific &#945;1-globulin (retinol-binding protein) in the blood. The retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid; these and other metabolites are excreted in urine and faeces.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ribavirin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Caution should be exercised when abacavir and ribavirin are coadministered. As abacavir and ribavirin share the same phosphorylation pathways a possible intracellular interaction has been postulated which could decrease ribavirin intracellular phosphorylated metabolites and result in a reduced likelihood of SVR. While some initial data suggested HIV/HCV co-infected patients receiving abacavir-containing regimens may be at risk of lower response to ribavirin therapy, this has not been confirmed in more recent studies. In addition a well-designed study to evaluate the effects of abacavir on intracellular ribavirin triphosphate and plasma ribavirin concentrations failed to show any significant effect.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Caution should be exercised when abacavir and ribavirin are co-administered. As ABC and RBV share the same phosphorylation pathways, a possible intracellular interaction between these drugs has been postulated, which could lead to a reduction in intracellular phosphorylated metabolites of ribavirin and, as a potential consequence, a reduced chance of sustained virological response (SVR) for Hepatitis C (HCV) in HCV co-infected patients treated with pegylated interferon plus RBV. Conflicting clinical findings are reported in literature on co-administration between abacavir and ribavirin. Some data suggest that HIV/HCV co-infected patients receiving abacavir-containing ART may be at risk of a lower response rate to pegylated interferon/ribavirin therapy.<br><em>Ziagen Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2011.<br><br></em></div>

<div>
<div>Ribavirin steady state Cmin was prospectively determined in pharmacokinetic substudy on 124 HIV-HCV coinfected patients receiving ribavirin plus Peg-IFN from the ANRS CO-13 HEPAVIH cohort. Of these patients, 22% received abacavir. The overall median ribavirin Cmin was 1.6 mg/L with no statistical difference between abacavir users and non-users. There was no difference in the proportion of abacavir users versus non-users achieving RVR (respectively 59% versus 50%, p=0.40) or EVR (72% versus 73%, p=0.94), or in the HCV-RNA decline at week 4 or 12. The SVR rate was 45% for abacavir users and 24% for abacavir non-users, but the difference was not statistically significant (p=0.059). <br><em>Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? Solas C, Pambrun E, Winnock M, et al. AIDS, 2012, Epub ahead of print.</em></div>
<div>&nbsp;</div>
<div>To determine if use of abacavir, and other antiretrovirals were associated with reduced response to pegylated interferon plus ribavirin, a cohort study was performed among antiretroviral-treated HIV/HCV patients initiating PEG-interferon plus ribavirin (n=212). 74 patients (35%) received abacavir. No differences were observed between abacavir users and non-users in early virologic response or sustained virologic response. No association was found between other antiretrovirals and lack of early or sustained response.<br><em>The influence of abacavir and other antiretroviral agents on virologic response to hepatitis C virus therapy among antiretroviral-treated HIV-infected patients. Amorosa V, Slim J, Mounzer K et al. Antivir Ther. 2010 ; 15: 9199.</em> </div>
<div>
<p>In order to assess the influence of antiretrovirals on hepatitis C treatment with ribavirin and peginterferon, the outcomes of 493 HIV positive patients receiving first line treatment for hepatitis C were retrospectively analysed. Among the factors associated with lack of sustained virological response according to multivariate analysis, a trend was observed with abacavir use, which was significant in patients with lower ribavirin plasma levels (&lt;2.3 g/ml). Use of abacavir may interfere with anti-HCV efficacy of peginterferon and ribavirin treatment. As both ribavirin and abacavir are guanosine analogues, an inhibitory competition between both agents may explain this observation.<br><em>Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Vispo E, Barreiro P, Pineda JA&nbsp; Antivir Ther. 2008;13:429-37.</em></p>
<p>In multivariate analysis of data from the French HC02-Ribavic Study, concomitant treatment with abacavir and pegIFN + ribavirin was associated with an adjusted 4.9 fold increase in the risk of non-response to anti-HCV therapy. Ribavirin can affect intracellular NRTI anabolite levels by inhibiting the enzyme IMP dehydrogenase and it is intriguing to speculate that alterations of carbovir triphosphate levels (the active metabolite of abacavir) may be at least part of the reason for the observed effect. <br><em>Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? Bani-Sadr F, et al. J Acquir Immune Defic Syndr, 2007, 45: 123-125.</em></p></div></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Riboflavin (Vitamin B2)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Riboflavin is absorbed from the GI tract and in the circulation is bound to plasma proteins. Although widely distributed, little is stored in the body, and amounts in excess of requirements are excreted in the urine.<br /><em>Vitamin B Compound Strong Tablets UK Summary of Product Characteristics, Actavis UK Ltd, updated July 2012</em></p>
<p>Riboflavin is readily absorbed from the gastrointestinal tract. Although riboflavin is widely distributed to body tissues little is stored in the body. Riboflavin is converted in the body to the coenzyme flavine mononucleotide (FMN; riboflavin 5&#8242;-phosphate) and then to another coenzyme flavine adenine dinucleotide (FAD). About 60% of FMN and FAD are bound to plasma proteins. Riboflavin is excreted in urine, partly as metabolites. As the dose increases, larger amounts are excreted unchanged.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em> <br /></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rifabutin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifabutin is mainly metabolized by CYP3A4 and cholinesterase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rifampicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Potential decrease in abacavir plasma concentrations. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Potent enzymatic inducers such as rifampicin, phenobarbital and phenytoin may via their action on UDP-glucuronyltransferases slightly decrease the plasma concentrations of abacavir. <br /><em>Ziagen Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rifapentine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as rifapentine is deacetylated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rifaximin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in faeces, almost entirely as unchanged drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rilpivirine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. No clinically relevant drug-drug interaction is expected when rilpivirine is co-administered with abacavir. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration with abacavir has not been studied. No clinically relevant drug-drug interactions are expected. No dose adjustment is required.</div>
<div><em>Edurant Summary of Product Characteristics, Janssen-Cilag Ltd, November 2011.</em>
<div>&nbsp;</div>No clinically relevant drug-drug interaction is expected when rilpivirine is co-administered with abacavir.</div>
<div><em>Edurant Prescribing Information, Tibotec Inc, May 2011.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rilpivirine/FTC/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Odefsey is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Odefsey is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products.<br><em>Odefsey Summary of Product Characteristics, Gilead Sciences Ltd, June 2016.</em></p>

</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rimantadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rimantadine is both hydroxylated and glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Risperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Risperidone is metabolized by CYP2D6 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ritonavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rituximab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rituximab is a monoclonal IgG antibody. Elimination is similar to endogenous IgG and occurs primarily via proteolytic catabolism throughout the body.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rivaroxaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Rivaroxaban is partly metabolized in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rizatriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rizatriptan is metabolized by oxidative deamination by monoamine oxidase-A (MAO-A).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rocuronium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Rocuronium is mostly cleared in the bile although up to 30% may be excreted renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ropinirole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ropinirole is metabolised predominantly by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rosiglitazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Rosuvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as rosuvastatin is largely excreted unchanged via the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sacubitril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sacubitril is rapidly converted to LBQ657 (active metabolite) by carboxylesterases and the active metabolite is not further metabolized to a significant extent.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Salbutamol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-4-O-sulphate. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Salmeterol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Saquinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Saw palmetto (Serenoa repens)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Saxagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4/5 but does not inhibit or induce this enzyme. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Senna</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions. No clinically significant drug interactions are known.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>There is some absorption of anthraquinone laxatives following administration by mouth. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions including breast milk. No clinically significant drug interactions are known.<br /><em>Senna Laxative Tablets, UK Summary of Product Characteristics, The Boots Company PLC, updated February 2008</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sertraline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Seville orange juice</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sevoflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as sevoflurane is almost exclusively eliminated unchanged by the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sildenafil (Erectile Dysfunction)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sildenafil (Pulmonary Arterial Hypertension)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Simeprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but no clinically relevant drug-drug interaction is expected. No dose adjustment is required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied. No clinically relevant drug drug interaction is expected. No dose adjustment is required.</div><div><em>Olysio Summary of Product Characteristics, Janssen-Cilag, May 2014.</em></div><div>&nbsp;</div><div>No clinically relevant drug-drug interaction is expected when simeprevir is co-administered with abacavir.</div><div><em>Olysio US Prescribing Information, Janssen, December 2013.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Simvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sirolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sirolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sitagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, P-gp) and metabolism by CYP3A4 represents a minor elimination pathway. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sodium nitroprusside</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. There is little potential for sodium nitroprusside to affect the disposition of antiretrovirals, or to be affected if co-administered with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Sodium nitroprusside is rapidly metabolized, probably by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase (rhodanase). This mitochondrial enzyme normally is present in excess quantities such that the rate-limiting step in the conversion of cyanogen to thiocyanate usually is the availability of sulfur donors (e.g., thiosulfate, cystine, cysteine). Sodium nitroprusside is excreted entirely as metabolites, principally thiocyanate. In animals, sodium nitroprusside metabolites are excreted mainly in urine, exhaled air, and probably in feces. The elimination half-life of thiocyanate is 2.7&#8211;7 days when renal function is normal but is longer in patients with impaired renal function or hyponatremia.<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, 01/2009</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sodium stibogluconate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Elimination of sodium stibogluconate is predominantly via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Following intravenous or intramuscular administration of sodium stibogluconate, antimony is excreted rapidly via the kidneys, the majority of the dose being detected in the first 12-hour urine collection. This rapid excretion is reflected by a marked fall in serum or whole blood antimony levels to approximately 1 to 4% of the peak level by 8 hours after an intravenous dose. During daily administration, there is a slow accumulation of sodium stibogluconate into the central compartment so that tissue concentrations reach a theoretical maximum level after at least 7 days<br /><em>Pentostam&#174; (sodium stibogluconate) injection UK Summary of Product Characteristics, GlaxoSmithKline UK, updated August 2007</em></p>
<p>The renal excretion of sodium stibogluconate was studied in patients with kala azar and in volunteers; both urine and serum levels of sodium stibogluconate were measured. After intravenous injection sodium stibogluconate seemed to be distributed throughout the extracellular fluid and to have a renal clearance similar to that of inulin. After intramuscular injection, peak blood levels were lower and more sustained. However, more than 80% was excreted in the first 6 h, and blood levels fell to around 1% of peak values in 16 h. The dangers of cumulative toxicity may be exaggerated, and restriction of courses of sodium stibogluconate to 30 days or even to 10 days may not be necessary. <br /><em>Renal clearance of pentavalent antimony (sodium stibogluconate). Rees PH, Keating MI, Kager PA, Hockmeyer WT. Lancet. 1980 Aug 2;2(8188):226-9</em></p>
<p>The pharmacokinetics of sodium stibogluconate was examined in 29 patients with cutaneous leishmaniasis following intramuscular administration of sodium stibogluconate equivalent to 600mg of antimony (Sb). The blood concentration-time data conformed to the one-compartment open model with mean and (SEM) of the apparent first-order rate constants for absorption (ka) and elimination (kd) of 1.71 (0.15) and 0.391 (0.016) hr-1, respectively. The total body clearance (TBC) and the volume of distribution (Vd) were 17.67 (1.38) L/hr and 45.7 (2.6) L, respectively, assuming a complete absorption. The fraction of dose of Sb excreted in the urine was 0.80 (0.07) and the renal clearance was 12.7 (1.16) L/hr. <br /><em>Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Jaser MA, el-Yazigi A, Croft SL. Pharm Res. 1995 Jan;12(1):113-6</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Based on metabolism and elimination there is little potential for interaction as abacavir metabolism is mediated by UDP-glucuronyltransferases which are not affected by sofosbuvir. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Solifenacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Solifenacin is metabolized by CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sorafenib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Sorafenib is metabolized to a moderate extent by CYP3A4 and UGT1A9, UGT1A1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Spectinomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Spectinomycin is predominantly eliminated unchanged by the kidneys via glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Spironolactone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolized by the flavin containing monooxygenases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Stanozolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Stavudine (d4T)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>St John&#39;s Wort</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. St Johns wort is unlikely to affect the exposure of NRTIs such as abacavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Streptokinase</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Streptokinase is unlikely to affect the disposition of antiretrovirals, or to be affected if co-administered with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The elimination kinetics of streptokinase follows a biphasic course. A small proportion of the dose is bound to anti-streptokinase antibodies and metabolised with a half-life of 18 minutes, whilst most of it forms the streptokinase-plasminogen activator complex and is biotransformed with a half-life of about 80 minutes. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys.<br /><em>Streptokinase 750,000 iu UK Summary of Product Characteristics, Beacon Pharmaceuticals, updated August 2012</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Streptomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is excreted rapidly in the urine by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Strontium ranelate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as strontium ranelate is not metabolised and is excreted unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sufentanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as sufentanil undergoes extensive CYP3A4 metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sulfadiazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. In vitro studies suggest that sulfadiazine is metabolized in part by CYP2C9. Adverse reactions to sulfadiazine are thought to be more common in patients with AIDS.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Sulfadiazine is readily absorbed from the gastrointestinal tract and peak blood concentrations occur 3 to 6 hours after a single dose; 20 to 55% has been reported to be bound to plasma proteins. It penetrates into the CSF within 4 hours of an oral dose to produce therapeutic concentrations, which may be more than half those in the blood. Up to 40% of sulfadiazine in the blood is present as the acetyl derivative. About 50% of a single dose of sulfadiazine given orally is excreted in the urine in 24 hours; 15 to 40% is excreted as the acetyl derivative. The urinary excretion of sulfadiazine and the acetyl derivative is dependent on pH. About 30% is excreted unchanged in both fast and slow acetylators when the urine is acidic whereas about 75% is excreted unchanged by slow acetylators when the urine is alkaline.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em></p>
<p>The sulfadiazine hydroxylamine metabolite has been linked to greatly increased rates of adverse reactions to sulfadiazine experienced by people with HIV infection. A study investigated the in vitro human cytochrome P450 (P450) and N-arylamine acetyltransferase (detoxification) metabolism of sulfadiazine. Formation of both the hydroxylamine and 4-hydroxy sulfadiazine was NADPH-dependent in human liver microsomes (HLM). Significant (p &lt; 0.05) inhibition by selective P450 isoform inhibitor sulfaphenazole (2.1 microM; CYP2C9) indicated a role for CYP2C9 in the formation of the hydroxylamine. Hydroxylamine formation correlated strongly with tolbutamide 4-hydroxylation (CYP2C8/9) in HLM (r = 0.76, p &lt; or = 0.004, n = 12). Fluconazole (CYP2C9/19 and CYP3A4 inhibitor at clinical concentrations) inhibited hydroxylamine formation, with one-enzyme model K(i) estimates ranging from 9 to 40 microM. Acetylation of sulfadiazine in human liver cytosol (HLC) correlated strongly with NAT2 activity as measured by sulfamethazine N-acetylation (r = 0.92, p &lt; 0.001, n = 12).&nbsp; The polymorphic acetylation of sulfadiazine may predispose slow acetylator patients to adverse reactions to sulfadiazine. On the basis of our K(i) estimates, clinical fluconazole concentrations of 25 microM would produce decreases of 40 to 70% in hepatic-mediated hydroxylamine production. Therefore, we predict that fluconazole may prove useful in the clinic as an in vivo inhibitor of sulfadiazine hydroxylamine formation to suppress adverse reactions to this drug.<br /><em>Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Winter HR, Unadkat JD. Drug Metab Dispos. 2005 Jul;33(7):969-76.<br /></em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sulfadoxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sulfasalazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction. Multiple mechanisms are thought to be involved in sulfasalazine metabolism including acetylation, hydroxylation, and glucuronidation. There is therefore low potential for clinically significant interactions with abacavir via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Around 90% of a dose reaches the colon where bacteria split the drug into sulfapyridine (SP) and mesalazine (ME). These are also active, and the unsplit sulfasalazine (SASP) is also active on a variety of symptoms. Most SP is absorbed, hydroxylated or glucuronidated and a mix of unchanged and metabolised SP appears in the urine. Some ME is taken up and acetylated in the colon wall, such that renal excretion is mainly AC-ME. SASP is excreted unchanged in the bile and urine. Turning to mesalazine, in urine only AC-ME (not free ME) was demonstrable, the acetylation probably largely achieved in the colon mucosa. After a 3g SASP dose lag time was 6.1&#177;2.3 hours and plasma levels kept below 2&#181;g/ml total ME. Urinary excretion half life was 6.0&#177;3.1 hours and absorption half life based on these figures 3.0&#177;1.5 hours. Renal clearance constant was 125ml/min corresponding to the GFR.<br /><em>Salazopyrin En-Tabs&#174; (Sulfasalazine) UK Summary of Product Characteristics, Pfizer Limited, updated August 2010</em></p>
<p>Sulfasalazine is metabolised by intestinal bacteria to sulfapyridine (SP) and 5-ASA. Approximately 15% of a dose of sulfasalazine is absorbed as parent and is metabolised to some extent in the liver to the same two species. The observed plasma half life for IV sulfasalazine is 7.6 &#177;3.4 hrs. The primary route of metabolism of SP is via acetylation to form AcSP. The rate of metabolism of SP to AcSP is dependent upon acetylator phenotype. SP can also be metabolised to 5-hydroxy-sulfapyridine and N-acetyl-5-hydroxy-sulfapyridine. 5-ASA is primarily metabolised in both the liver and intestine to N-acetyl-5-aminosalicylic acid via a non-acetylation phenotype dependent route. Due to low plasma levels produced by 5-ASA after oral administration, reliable estimates of plasma half lives are not possible. Absorbed SP and 5-ASA and their metabolites are primarily eliminated in the urine either as free metabolites or glucuronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl 5-ASA within the feces. The calculated clearance of sulfasalazine following IV administration was 1L/hr. Renal clearance was estimated to account for 37% of total clearance.<br /><em>Sulfasalazine tablets USP US Prescribing Information, Watson Laboratories Inc, updated May 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sulpiride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulpiride is mainly excreted in the urine and faeces as unchanged drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sumatriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sumatriptan is eliminated primarily by metabolism mediated by monoamine oxidase A.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Sunitinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Sunitinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Suramin sodium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Suramin appears to be eliminated predominantly unchanged via renal glomerular filtration. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The clinical pharmacokinetics of suramin were studied in 4 patients with AIDS given 6.2 g intravenously over 5 weeks. Suramin accumulated during treatment and plasma concentrations exceeded 100 micrograms/mL for several weeks. After the last dose the terminal half-life of suramin ranged from 44 to 54 days. At least 99.7% was bound to plasma proteins. Renal clearance accounted for most (80%) of the elimination of suramin from the body. There appeared to be little or no metabolism of suramin.<br /><em>Collins JM, Klecker RW Jr, Yarchoan R, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 1986 Jan;26(1):22-6.</em></p>
<p>Suramin was administered to 49 patients in a Phase I cancer trial with real-time pharmacokinetic monitoring and dose individualization to achieve targeted mean plasma concentrations of 210 and 155 mg/liter during the 7-day period between days 15 and 22. Pharmacokinetic sampling after doses on days 1, 3, 5, and 8 was used to modify weekly suramin doses, beginning on day 15, in an attempt to achieve specific averaged plasma concentrations of 210 and 155 mg/liter. A 200-mg test dose was not effective in prospectively determining individual pharmacokinetic parameters and dosage requirements. Prospective use of surrogate substrates for CYP1A2, CYP3A3/4, and CYP2D6 showed no consistent effect of suramin on these enzymes. Although a correlation between creatinine clearance and suramin renal clearance was found (r2 = 0.38; P &lt; 0.00005), there was no correlation between creatinine clearance and total suramin clearance (P = 0.21). As expected for a drug eliminated renally by filtration, the extrapolated intercept of suramin renal clearance approximates zero at a creatinine clearance of 0 ml/min<br /><em>Hutson PR, Tutsch KD, Rago R, Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. Clin Cancer Res. 1998 Jun;4(6):1429-36.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Suxamethonium (Succinylcholine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Suxamethonium is hydrolysed by plasma cholinesterase. There is therefore little potential for interaction with abacavir via modulation of or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Following intravenous administration, there is rapid hydrolysis by pseudocholinesterase with the initial metabolite being succinylmonocholine a weak neuro-muscular drug. This is metabolised to succinic acid with only a small amount excreted in the urine.<br /><em>Suxamethonium Chloride Injection BP UK Summary of Product Characteristics, Mercury Pharma Group, updated May 2012</em></p>
<p>Succinylcholine is rapidly hydrolyzed by plasma cholinesterase to succinylmonocholine (which possesses clinically insignificant depolarizing muscle relaxant properties) and then more slowly to succinic acid and choline. About 10% of the drug is excreted unchanged in the urine.<br /><em>Anectine&#174; (Succinylcholine Chloride Injection, USP) US Prescribing Information, Sandoz Inc, updated September 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tacrolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tacrolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tadalafil (Erectile Dysfunction)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tadalafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tadalafil (Pulmonary Arterial Hypertension)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tadalafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tamoxifen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 > 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tamsulosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Telaprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telaprevir is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Telbivudine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telbivudine is eliminated primarily by urinary excretion as unchanged drug. The renal clearance of telbivudine approaches normal glomerular filtration rate, suggesting that filtration is the main mechanism of excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Telithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telithromycin is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Telmisartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telmisartan is mainly glucuronidated by UGT1A3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Temazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as temazepam is mainly glucuronidated. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Temsirolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Temsirolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tenofovir-DF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of tenofovir-DF (300 mg once daily) and abacavir (300 mg single dose) had no effect on tenofovir AUC or Cmax, and abacavir AUC; abacavir Cmax increased by 12%. A high rate of virological failure and emergence of resistance have been reported when lamivudine was combined with tenofovir-DF and abacavir as a once daily regimen. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Triple NRTI Therapy<br />There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when abacavir was combined with tenofovir disoproxil fumarate and lamivudine as a once daily regimen. <br /><em>Ziagen Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2011.</em></p>
<div>Triple NRTI Therapy:<br />There have been reports of a high rate of virological failure and of emergence of resistance at early stage when tenofovir disoproxil fumarate was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen. <br /><em>Viread Summary of Product Characteristics, Gilead Sciences Ltd, May 2015.</em> 
<div>&nbsp;</div>Coadministration of tenofovir-DF (300 mg once daily) and abacavir (300 mg single dose) was studied in 8 HIV-negative subjects. There was no change in tenofovir AUC or Cmax; abacavir AUC was unaltered and Cmax increased by 12%. <br /><em>Viread Prescribing Information, Gilead Sciences International Inc, May 2015.</em></div>
<p>The plasma and intracellular pharmacokinetic interaction between tenofovir and abacavir, lamivudine or lopinavir was investigated in HIV+ subjects receiving TDF + 3TC/LPV (n=7), TDF + 3TC/NVP (n=8), TDF + ABC/LPV (n=7) or TDF + ABC/NVP (n=5). Between group comparisons showed no significant interaction between tenofovir and abacavir or lamivudine. <br /><em>A pharmacokinetic study in HIV infected patients under tenofovir fumarate: investigation of systemic and intracellular interaction between TDF and abacavir, or lamivudine or lopinavir/ritonavir. Pruvost A, et al. 8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, April 2007, abstract 56.</em></p>
<p>The effect of stopping abacavir on the intracellular pharmacokinetics of tenofovir was studied in 7 HIV-infected subjects initially receiving abacavir and tenofovir with lamivudine or stavudine. Intracellular levels of tenofovir-diphosphate did not demonstrate evidence of substantial changes over time after discontinuation of abacavir. Median TDF-DP concentrations prior to and 1 month after discontinuation were 89.9 and 89.6 fmol/10^6 cells, respectively. <br /><em>Intracellular pharmacokinetics of tenofovir disphosphate, carbovir triphosphate and lamivudine triphosphate in patients receiving triple-nucleoside regimens. Hawkins T, et al. J Acquir Immune Defic Syndr, 2005, 39: 406-411.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Terazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as terazosin is extensively metabolized in the liver possibly via CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Terbinafine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Terbinafine is metabolized by CYP1A2, 2C9, 3A4 and to a lesser extent CYP2C8 and 2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Terfenadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terfenadine undergoes extensive metabolism mainly by CYP3A4 to form azacyclonol and terfenadine alcohol.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Testosterone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely as testosterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tetracaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Absorbed tetracaine is predominantly metabolised by pseudocholinesterases in the plasma.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Tetracaine undergoes rapid mucosal absorption and is heavily protein-bound in blood. Tetracaine is metabolised in the liver (and sometimes in the kidney) to para-aminobenzoic acid<br /><em>Eludril&#174; Spray (Tetracaine hydrochloride/Chlorhexidine digluconate) UK Summary of Product Characteristics, Pierre Fabre Limited, updated January 2011</em></p>
<p>Tetracaine is hydrolysed in the body to p-amino-benzoic acid and should not therefore be used in patients being treated with sulphonamides.&nbsp; The primary site of metabolism for tetracaine is the plasma. Pseudocholinesterases in the plasma hydrolyse tetracaine to 4-aminobenzoic acid. Unmetabolised drug is excreted in the urine<br /><em>Minims Tetracaine Hydrochloride 1.0% w/v eye drops UK Summary of Product Characteristics, Bausch &amp; Lomb U.K Limited, updated July 2008</em></p>
<p>Tetracaine is reported to be about 15% bioavailable after application of a 4% gel to intact skin, with a mean absorption and elimination half-life of about 75 minutes.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via medicines Complete), latest modification: 05-Dec-2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tetracyclines</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Tetracyclines are eliminated unchanged primarily by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Thalidomide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as thalidomide is cleared by non-enzymatic hydrolysis.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Theophylline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Thiamine (Vitamin B1)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Thiamine is absorbed from the GI tract and is widely distributed to most body tissues. It is not stored to any appreciable extent in the body and amounts in excess of requirements are excreted in the urine as unchanged thiamine or metabolites.<br /><em>Vitamin B Compound Strong Tablets UK Summary of Product Characteristics, Actavis UK Ltd, updated July 2012</em></p>
<p>Small amounts of thiamine are well absorbed from the gastrointestinal tract after oral doses, but the absorption of doses larger than about 5 mg is limited. It is also rapidly absorbed on intramuscular injection. It is widely distributed to most body tissues. Within the cell, thiamine is mostly present as the diphosphate. Thiamine is not stored to any appreciable extent in the body and amounts in excess of the body's requirements are excreted in the urine unchanged or as metabolites.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Thiopental</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Thiopental is almost completely metabolised in the body with a very small percentage excreted unchanged in urine. Ring desulfuration to the corresponding oxibarbiturate, pentobarbital, retains pharmacological activity. This active metabolite represents 3.3 to 3.6% of an anaesthetic dose and 10% of the parent concentration in the blood of patients receiving high dose thiopental therapy. Both thiopental and pentobarbital undergo oxidation on the terminal carbon atom of the 1-methyl-butyl side chain in the course of metabolic transformation and leads to thiopental carboxylic acid and pentobarbital carboxylic acid, which are pharmacologically inactive. A second metabolic pathway leads to thiopental alcohol and pentobarbital alcohol (metabolites without activity) by hydroxylation in position 3 of the methyl-butyl side chain. Oxidation to the thiopental carboxilic acid is the major step of detoxification in humans, and the urinary excretion of this product accounted for about 10 to 25% of the administered doses. It seems that the main determining factor in the metabolism rate is not the activity of the microcomal enzyme systems but the slow thiopental release from fat deposits. <br /><em>Pharmacodynamics and pharmacokinetics of thiopental. Russo H, Bressolle F. Clin Pharmacokinet. 1998 Aug;35(2):95-134</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Thioridazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thioridazine is metabolized by CYP2D6 and to a lesser extent by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tiapride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tiapride is excreted largely unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ticagrelor</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticagrelor undergoes extensive CYP3A4 metabolism and is only a mild inhibitor of CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Timolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction when timolol is used either orally or as eye drops. Timolol is predominantly metabolised via CYP2D6, there is therefore little potential for interaction with abacavir via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Like other topically applied ophthalmic drugs, 'Timoptol' may be absorbed systemically and adverse reactions seen with oral beta-blockers may occur.<br /><em>Timoptol&#174; (Timolol) 0.25% and 0.5% w/v Eye Drops Solution UK Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated June 2008</em></p>
<p>An in vitro study identified four timolol metabolites, the most abundant being a hydroxy metabolite, M1. Metabolism of timolol with recombinant P450s and correlation analysis confirmed that the drug is metabolized principally by CYP2D6, CYP2C19 being only a minor contributor (&lt;10%) to the intrinsic microsomal clearance. The CYP2D6 inhibitor quinidine proved a potent competitive inhibitor of timolol metabolism, with an in vitro K(i) value of 0.08 microM. Fluvoxamine, an inhibitor of CYP2C19, inhibited timolol metabolism to a lesser extent, confirming its minor contribution. Timolol itself did not inhibit CYP2D6-catalyzed dextromethorphan O-demethylation. Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo. The inhibition of timolol metabolism by quinidine should be taken into account when patients are treated with timolol. However, when plasma timolol concentrations in patients remain low (&lt; or = 0.2 microg/l), it is suggested that such interaction is of minor clinical relevance.<br /><em>Volotinen M, Turpeinen M, Tolonen A et al. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos. 2007 Jul;35(7):1135-41</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tipranavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of tipranavir/ritonavir decreased abacavir exposure by ~40%. The clinical relevance of the reduction in abacavir levels has not been established. Coadministration is not recommended unless there are no other available NRTIs suitable for patient management. In such cases no dosage adjustment of abacavir can be recommended. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>&nbsp;</p>
<div>Coadministration of abacavir (300 mg twice daily) and tipranavir/ritonavir (750/100 mg twice daily) decreased abacavir Cmax and AUC by 46% and 36%. The clinical relevance of this reduction has not been established, but may decrease the efficacy of abacavir. The concomitant use of tipranavir, co-administered with low dose ritonavir, with abacavir is not recommended unless there are no other available NRTIs suitable for patient management. In such cases no dosage adjustment of abacavir can be recommended.<br /><em>Aptivus Summary of Product Characteristics, Boehringer Ingelheim International GmbH, December 2011.</em></div>
<p>The pharmacokinetics of abacavir (300 mg bd) were studied in HIV+ subjects when coadministered with tipranavir/ritonavir (250/200 mg bd, n=28; 750/100 mg bd, n=14; 1250/100 bd, n=11). Abacavir Cmax and Cmin decreased by 44% with tipranavir/ritonavir 250/200 mg, decreased by 46% and 36% with tipranavir/ritonavir 750/100 mg and decreased by 52% and 35% with tipranavir/ritonavir 1250/100 mg. The clinical relevance of the ~40% reduction in abacavir levels not established. Dose adjustment of abacavir cannot be recommended at this time.<br /><em>Aptivus Prescribing Information, Boehringer Ingelheim, April 2012.</em></p>
<p>The addition of tipranavir/ritonavir (1250/100 mg, n=11; 750/100 mg, n=14; 250/100 mg, n=28) was studied in HIV+ subjects on stable HAART regimens containing abacavir. Reductions in abacavir AUC were observed; however, the clinical significance of these findings is unclear. Pharmacokinetic drug interaction screen of three doses of tipranavir/ritonavir in HIV-infected patients on stable highly active antiretroviral therapy. <br /><em>Goebel FD, Sabo JP, MacGregor TR, et al. HIV DART, Naples (Florida), December 2002.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tizanidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as tizanidine is metabolised by CYP1A2.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tolbutamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tolbutamide is mainly metaboliized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tolterodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 having a major role in CYP2D6 poor metabolisers.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Topiramate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Topotecan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration has not been studied. Topotecan undergoes both hepatic and renal elimination. Hepatic elimination involves mainly non-enzymatic hydrolysis and, to a minor extent, CYP mediated N-demethylation as well as glucuronidation. Renal elimination is by both active secretion (mainly via OAT3) and glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Torasemide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as torasemide is mainly metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Toremifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Toremifene is mainly metabolized by CYP3A4 to N-demethyltoremifene.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tramadol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Trandolapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as trandolapril is hydrolysed to trandolaprilat.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tranexamic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranexamic acid is mainly cleared by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Tranylcypromine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranylcypromine is hydroxylated and acetylated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Trazodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as trazodone is primarily metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Triamcinolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as triamcinolone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Triazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as triazolam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Triclabendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Triclabendazole appears to be metabolised in part by CYP450 enzymes, whereas abacavir is metabolised by alcohol dehydrogenase and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In vivo, triclabendazole is rapidly oxidised into its sulfoxide metabolite, which is further oxidised to the sulfone metabolite. The sulfoxide form is predominant in plasma, with the parent compound and the sulfone metabolite having AUCs respectively of approximately 1% and 10% of that of the sulfoxide. The rapid biotransformation of triclabendazole in man and the previous findings in animals produced evidence of presystemic biotransformation including first-pass metabolism of triclabendazole. In animals, the drug is largely excreted via the biliary tract in the faeces (90%), together with the sulfoxide and subsequently the sulfone metabolite. Less than 10% of an oral dose is excreted in the urine.<br /><em>Egaten&#174; Summary of product Charateristics, Novartis Pharma AG Basel, Switzerland, Produced July 2000</em></p>
<p>Ketoconazole, a CYP450 enzyme inhibitor was found to inhibit metabolism of triclabendazole in vitro<br /><em>Devine C, Brennan GP, Lanusse CE, et al. Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol Res. 2011 Oct;109(4):981-95.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Trimethoprim/Sulfamethoxazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Trimethoprim and sulfamethoxazole are eliminated by the kidneys through glomerular filtration and tubular secretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Trimipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Trospium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Turmeric (Curcuma longa)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Data from pharmacokinetic studies suggest that curcuminoids (derived from turmeric extract) are unlikely to affect UGT-mediated metabolism.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ulipristal</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Ulipristal is mainly metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Valaciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valaciclovir is converted to aciclovir which is eliminated renally via glomerular filtration and active renal secretion by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Valerian</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Valproate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as valproate is glucuronidated by several UGTs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Valsartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as valsartan is eliminated unchanged mostly through biliary excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Vancomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Vancomycin is predominantly eliminated unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Vancomycin is metabolized only to a low extent. After parenteral administration it is excreted almost completely as microbiologically active substance (approx. 75-90% within 24 hours) through glomerular filtration via the kidneys. Biliary excretion is insignificant (less than 5% of a dose). The clearance of vancomycin from plasma correlates nearly with the glomerular filtration rate. No vancomycin metabolites have been identified so far in humans<br /><em>Vancomycin, 500 mg, powder for solution for infusion Summary of Product Characteristics, Sandoz Limited, updated November 2011</em></p>
<p>In the first 24 hours, about 75% of an administered dose of vancomycin is excreted in urine by glomerular filtration. Mean plasma clearance is about 0.058 L/kg/hr, and mean renal clearance is about 0.048 L/kg/hr. Renal dysfunction slows excretion of vancomycin. In anephric patients, the average half-life of elimination is 7.5 days. The distribution coefficient is from 0.3 to 0.43 L/kg. There is no apparent metabolism of the drug.<br /><em>Sterile vancomycin hydrochloride, USP Fliptop Vial For Intravenous Use, US Prescribing Information, Hospira Inc, updated December 2007</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Vardenafil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vardenafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Varenicline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interactions due to cytochrome P450 metabolism or renal secretion expected. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Based on varenicline characteristics and clinical experience to date, varenicline has no clinically meaningful drug interactions. No dosage adjustment of varneicline or co-administered medicinal products listed below is recommended. In vitro studies indicate that varenicline is unlikely to alter the pharmacokinetics of compounds that are primarily metabolised by cytochrome P450 enzymes. Furthermore since metabolism of varenicline represents less than 10% of its clearance, active substances known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline and therefore a dose adjustment of varenicline would not be required. In vitro studies demonstrate that varenicline does not inhibit human renal transport proteins at therapeutic concentrations. Therefore, active substances that are cleared by renal secretion are unlikely to be affected by varenicline. <br /><em>Champix Summary of Product Characteristics, Pfizer Ltd, August 2008.</em></p>
<p>No clinically meaningful pharmacokinetic drug-drug interactions have been identified. In vitro studies demonstrated that varenicline does not inhibit the following cytochrome P450 enzymes (IC50 &gt;6400 ng/mL): 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5. Also, in human hepatocytes in vitro, varenicline does not induce the cytochrome P450 enzymes 1A2 and 3A4. In vitro studies demonstrated the active renal secretion of varenicline is mediated by the human organic cation transporter, OCT2. Co-administration with inhibitors of OCT2 may not require a dose adjustment of varenicline as the increase in systemic exposure to varenicline is not expected to be clinically meaningful. Furthermore, since metabolism of varenicline represents less than 10% of its clearance, drugs known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline and therefore a dose adjustment of varenicline would not be required. <br /><em>Chantix Prescribing Information, Pfizer Inc, May 2008.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Velpatasvir/Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Abacavir can be administered with velpatasvir/sofosbuvir and no dose alteration is required. Abacavir is metabolised by UGTs which are not affected by velpatasvir/sofosbuvir.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Venlafaxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Verapamil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as verapamil is metabolised mainly by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Vercuronium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning the metabolism/elimination and toxicity profile of vercuronium, there is little potential for interaction with abacavir via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In man, urine recovery of vecuronium varies from 3 to 35% within 24 hours. Data derived from patients requiring insertion of a T-tube in the common bile duct suggests that 25 to 50% of a total intravenous dose of vecuronium may be excreted in bile within 42 hours. Only unchanged vecuronium has been detected in human plasma following use during surgery. In addition, one metabolite, 3-desacetyl vecuronium, has been rarely detected in human plasma following prolonged clinical use in intensive care units. The 3-desacetyl vecuronium metabolite has been recovered in the urine of some patients in quantities that account for up to 10% of injected dose; 3-desacetyl vecuronium has also been recovered by T-tube in some patients, accounting for up to 25% of the injected dose.<br /><em>Vecuronium bromide for injection US Prescribing Information, Pfizer Inc, updated February 2011</em></p>
<p>The metabolic fate of vecuronium bromide in humans has not been fully characterized. In vitro, vecuronium undergoes spontaneous deacetylation to form the hydroxy derivatives. The neuromuscular blocking activity of the 3&#945;-hydroxy derivative appears to be at least 50% that of the unchanged drug. In vitro, the 3&#945;-hydroxy derivative undergoes rapid conversion to the 3&#945;,17&#946;-dihydroxy derivative. The 17&#946;-hydroxy and 3&#945;,17&#946;-dihydroxy derivatives appear to have about 5 and 2% of the neuromuscular blocking activity of the unchanged drug respectively. The extent of spontaneous deacetylation and/or metabolism of vecuronium in humans remains to be clearly determined. Vecuronium bromide and its metabolite(s) appear to be excreted principally in feces via biliary elimination; the drug and its metabolite(s) are also excreted in urine. Although only unchanged drug has been detected in plasma in patients receiving the drug as an adjunct to surgical anesthesia, up to 10% of a dose of vecuronium bromide has been excreted in urine and 5&#8211;25% in bile as the 3&#945;-hydroxy derivative in some patients. Another metabolite, 3-desacetyl vecuronium, has been detected rarely in plasma following prolonged clinical use of the drug in an intensive care setting. Approximately 20&#8211;30% (range: 3&#8211;36%) of an IV dose of vecuronium bromide is excreted in urine within 24 hours after administration in humans, principally as unchanged drug and to a lesser extent as the 3&#945;-hydroxy derivative. In patients with a T-tube in the common bile duct, 12&#8211;45% of an IV dose of vecuronium was reportedly excreted in bile within 18&#8211;42 hours after administration, almost completely as unchanged drug. <br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, January 2009</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Vigabatrin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as vigabatrin is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Vildagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vildagliptin is inactivated via non-CYP mediated hydrolysis. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Vinblastine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vinblastine undergoes extensive metabolism and is excreted primarily by the biliary route.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Vincristine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vincristine is metabolized by CYP3A5/4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Vitamin E</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Voriconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as voriconazole is metabolised by CYPs 2C19, 2C9 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Vorinostat</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Vorinostat is mainly metabolised by glucuronidation (UGT2B17) and hydrolysis followed by B oxidation (non CYP-mediated).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Warfarin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYPs 1A2 and 3A4 whereas S-warfarin (more potent) is metabolized by CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Xipamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (50%) and glucuronides (30%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Zaleplon</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Zanamivir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. A small amount of the orally inhaled zanamivir is systematically absorbed. Absorbed zanamivir is excreted unchanged in the urine whereas unabsorbed zanamivir is excreted in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Zidovudine (AZT/ZDV)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No clinically significant interaction observed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Clinical studies have shown that there are no clinically significant interactions between abacavir, zidovudine, and lamivudine. <br /><em>Ziagen Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2011.</em></p>
<p>Due to the common metabolic pathways of abacavir and zidovudine via glucuronyl transferase, 15 HIV-infected patients were enrolled in a crossover study evaluating single doses of abacavir (600 mg), lamivudine (150 mg), and zidovudine (300 mg) alone or in combination. Analysis showed no clinically relevant changes in the pharmacokinetics of abacavir with the addition of lamivudine or zidovudine or the combination of lamivudine and zidovudine. Lamivudine exposure (AUC decreased 15%) and zidovudine exposure (AUC increased 10%) did not show clinically relevant changes with concurrent abacavir. <br /><em>Ziagen Prescribing Information, ViiV Healthcare, May 2012.</em></p>
<p>Multiple dose pharmacokinetics were determined in HIV-infected subjects following coadministration of abacavir (200, 400 or 600 mg three times daily or 300 mg twice daily) alone or with zidovudine (200 mg three times daily or 300 mg twice daily). Coadministration of zidovudine had only small and inconsistent effects on the steady state pharmacokinetics of abacavir that did not increase with dose. At the clinical abacavir dose (300 mg twice daily), zidovudine coadministration had no effect on abacavir AUC. The pharmacokinetic profiles of zidovudine in the absence of abacavir were not determined; however, mean AUC and Cmax values for zidovudine in the presence of abacavir were comparable to historical steady state values. <br /><em>Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. McDowell JA, et al. Antimicrob Agents Chemother, 2000, 44:2061-2067.</em></p>
<p>The pharmacokinetics and safety of single doses of abacavir (600 mg), zidovudine (300 mg) and lamivudine (150 mg) were evaluated when given alone or with either or both of the other drugs to 13 HIV-infected subjects. Coadministration of abacavir with zidovudine (with or without lamivudine) decreased ZDV Cmax by ~20%, delayed ZDV Tmax by 0.5h and increased AUC of zidovudine glucuronide by up to 40%. There were no differences in the pharmacokinetics of abacavir when given alone, or with zidovudine or lamivudine, or with both zidovudine and lamivudine.<br /><em>Single dose pharmacokinetics and safety of abacavir (1592U98), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Wang LH, et al. Antimicrob Agents Chemother, 1999, 43: 1708-1715.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Ziprasidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Zoledronic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Zoledronic acid is eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Zolpidem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Zonisamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Zopiclone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Zotepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Abacavir</p>
              <p>Zuclopenthixol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (by CYP2D6 and CYP3A4) and glucuronidation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


    </div>

  </div>

</div>

    <div class='commercial sponsors' id='sponsors'>
<div class='inner-wrapper'>
<div class='sponsors-title'>
SPONSORS
</div>
<a target="_blank" href="http://www.janssen.com/emea/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/001/tiny/sponsor-logo-janssen.png?1451996945" alt="Sponsor logo janssen" />
</a><a target="_blank" href="http://www.gilead.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/002/tiny/sponsor-logo-gilead.png?1451996988" alt="Sponsor logo gilead" />
</a><a target="_blank" href="http://www.msd-uk.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/003/tiny/sponsor-logo-msd.png?1451997044" alt="Sponsor logo msd" />
</a><a target="_blank" href="https://www.viivhealthcare.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/004/tiny/sponsor-logo-viiv.png?1451997075" alt="Sponsor logo viiv" />
</a><a target="_blank" href="http://www.abbvie.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/006/tiny/sponsor-logo-abbvie.png?1451997117" alt="Sponsor logo abbvie" />
</a><a target="_blank" href="http://www.bms.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/005/tiny/sponsor-logo-bristol-myers-squibb.png?1451997097" alt="Sponsor logo bristol myers squibb" />
</a></div>
</div>

<div class='editorial sponsors' id='sponsors'>
<div class='inner-wrapper'>
<div class='sponsors-title'>
EDITORIAL SPONSORS
</div>
<a target="_blank" href="http://www.bhiva.org/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/008/tiny/bhiva.jpg?1453297795" alt="Bhiva" />
</a><a target="_blank" href="http://www.hiv11.com/ContentPageView.aspx?ContentPageId=79"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/010/tiny/Glasgow.png?1453297904" alt="Glasgow" />
</a><a target="_blank" href="http://www.eacsociety.org/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/009/tiny/EACS_logo_2014.jpg?1453297878" alt="Eacs logo 2014" />
</a></div>
</div>


    <div class="footer">
  <div class="inner-wrapper">
    <div class="footer-left-column">
      <div class="footer-links">
        <a href="http://www.hiv-druginteractions.org/cookie-policy">Cookie Policy</a>
        <a href="http://www.hiv-druginteractions.org/privacy">Privacy Statement</a>
        <a href="http://www.hiv-druginteractions.org/terms">Terms &amp; Conditions</a>
      </div>
        <p>Last Review: January 20, 2017</p>

      <p>Copyright  2017 The University of Liverpool. All rights reserved.</p>
      <p>Designed and developed by the team at <a target="_blank" href="http://podmedics.org">Podmedics</a></p>
    </div>

    <div class="footer-right-column">

      <a href="https://www.liverpool.ac.uk/" target="_blank" class="footer-liverpool-logo"></a>

    </div>
  </div>
</div>

  </body>
  
</html>
